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ABSTRACT
Previous work in our lab indicates “stem-like” breast cancer cells can be identified 
by an ALDHhlCD44+ phenotype and that these cells are significantly more metastatic than 
ALDHlowCD44‘ cells. The purpose of this project was to investigate the functional role of 
overexpressed human ALDH1A1 in breast cancer behaviour. ALDH1A1 was stably 
overexpressed in MCF-7 human breast cancer cells and these cells were assessed using 
functional in vitro assays of metastasis (proliferation, adhesion, migration, colony 
formation). Despite overexpression of ALDH1A1, no significant differences were 
observed in malignant cell behaviour between empty vector control and MCF- 
7/ALDH1A1 cells. However, it was observed that MCF-7/ALDH1A1 cells with the 
highest ALDH activity demonstrate a significantly higher proportion of cells in the 
S/G2/M phases of the cell cycle relative to the remainder of the population (p<0.05). The 
results suggest that ALDH1A1 may not be the only ALDH isoform that plays a role in 
breast cancer metastasis.
Key Words: Aldehyde dehydrogenase 1A1 (ALDH1 Al), breast cancer, metastasis,
cancer stem cells
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Breast cancer remains the second leading cause of cancer mortality in Canadian 
women today [1]. Although many early stage breast cancers can be successfully treated 
by surgery, radiation, systemic cytotoxic and/or hormonal therapy, the majority of current 
therapies fail once the disease has spread to distant organs, or metastasized. Due to the 
complexity and multistep nature of metastasis, it is not surprising that this highly lethal 
process is also an inefficient one. Despite the small percentage of cancer cells from the 
primary tumour that are able to successfully metastasize, breast cancer metastasis remains 
a major contributor to cancer mortality in women due to the ineffectiveness of therapies 
in the metastatic setting [2-5]. It is therefore crucial to better understand the biology of 
metastasis so that we can develop more effective breast cancer therapies in the future. 
Previous data from our lab has demonstrated that we can successfully isolate “stem-like'’ 
breast cancer cells based on an high aldehyde dehydrogenase activity (ALDHhl) and 
CD44+ phenotype, and that these aggressive cells exhibit enhanced metastatic behaviour 
and therapy resistance compared to their ALDHlowCD44'counterparts [6, 7]. However, 
the functional role of aldehyde dehydrogenase (ALDH) in mediating breast cancer cell 
metastatic behaviour has not been investigated. Thus the focus of this thesis is on 





This year, there are estimated 171,000 new cases of cancer and 75,300 deaths 
from cancer that will occur in Canada [1 ]. Cancers are heterogeneous, multicellular 
entities that arise when an irreversible genetic change occurs in normal cells, thus 
disrupting the normal cellular homeostasis [8-10], These genetic alterations then favour 
the cancer cell’s uncontrolled proliferation, differentiation, migration, and extracellular 
matrix (ECM) metabolism, while restricting apoptosis, cellular polarity, and ECM 
stability due to the acquisition of six main malignant capabilities: Self-sufficiency in 
growth signals, insensitivity to inhibitory growth signals, sustained angiogenesis, evasion 
of apoptosis, unlimited replicated potential, and tissue invasion and metastasis [8, 9]. 
More recently, additional enabling characteristics have been identified, including 
genomic instability and mutation; tumour-promoting inflammation; evasion of immune 
destruction; altered metabolics; and the ability to recruit normal stromal cells to recreate a 
tumour microenvironment that benefits the tumour [10].
2.2 Breast Cancer
Breast cancer is not a single oncogenic disease, but rather is a diverse disease with 
various subtypes, phenotypes, molecular and clinical outcomes, and a variety of treatment 
responses [11]. It is currently accepted that there are five major molecular subtypes of 
breast cancer and they are conserved across ethnicities. These include basal-like, luminal
A, luminal B, human epidermal growth factor receptor 2 positive/estrogen receptor 
negative (HER2+/ ER') and normal breast-like breast tumours. In general, the basal-like 
breast tumours have a worse prognosis, while patients with luminal-A type have the best 
outcomes [11, 12]. Although breast cancer can occur in both men and women, it is more 
common in women, and is the second leading cause of cancer mortality in women in 
Canada [1]. Advances in primary breast cancer treatment and early detection allows for 
good prognosis and a high disease-free survival. Although many early stage breast 
cancers can be successfully treated by surgery, radiation, systemic cytotoxic and/or 
hormonal therapy, the majority of current therapies fail once the disease has spread to 
distant organs, or metastasized. Metastasis is therefore a major contributing factor to 
breast cancer mortality in Canada [2-5].
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2.3 Metastasis
The metastatic process involves a series of sequential steps, and all of these steps 
must be successfully completed by a cancer cell in order to give rise to a metastatic 
tumour in a distant secondary site {Figure 1) [3, 5, 13]. As the primary tumour grows, 
angiogenesis is sustained, so that cancer cells in the primary tumour can proliferate. The 
first step of metastasis occurs when a subset of tumour cells escape (or intravasate) 
through the basement membrane and surrounding tissues and disseminate into either the 
blood circulatory system or the lymphatic system [3, 5, 13]. This subset of cancer cells 
now must survive in the circulation, arrest in a new organ, and extravásate from the
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Maintenance of secondary macrometastasis
\
Primary tumour development
Recruitment of vasculature to primary tumour; 
beginning to become invasive
Tumour cell intravasates into circulation
Tumour cell arrests at and extravasates 
into a secondary site
Figure 1. Sequential steps of the metastatic cascade. (A) An oncogenic event 
occurs to transform the normal cells in the tissue into tumour cells. As the primary 
tumour grows, (B ) angiogenesis is sustained, so that cancer cells in the primary 
tumour can proliferate. (C) Tumour cells must then escape (or intravasate) through 
the basement membrane of the primary tumour and surrounding tissues and 
disseminate into either the blood circulatory system or the lymphatic system. This 
subset of cancer cells now must survive in the circulation, (D) arrest in a new organ, 
and extravásate from the circulation into the surrounding tissue of a secondary site. 
(E) Once in the secondary site, the cancer cells must initiate and maintain the 
growth to form micrometastases, (F) followed by the maintenance of growth into 
clinically detectable macrometastases. Adapted from Allan (2009), Chapter 3: 
Metastasis, Kuerer’s Breast Surgical Oncology, 2009: 27-39.
circulation into the surrounding tissue of a secondary site. Once in the secondary site, the 
cancer cells must initiate and maintain the growth to form micrometastases, followed by 
the maintenance of growth into clinically detectable macrometastases [3, 5, 13].
Due to the complexity and multistep nature of metastasis, it is not surprising that 
this highly lethal process is also an inefficient one. However, not all the steps are equally 
inefficient [2, 13-15]. Leonard Weiss was one of the first to observe metastatic 
inefficiency [16-19]. He found that only a small population of cancer cells in primary 
tumours have the ability metastasize, whereas the majority of the cells die after escaping 
from the primary tumour and attempting to survive in the circulation [18, 19], In a rat 
experimental model where radiolabelled Walker-256 (W-256) rat carcinoma cells were 
injected through the tail vein or directly into the liver of rats, metastatic inefficiency was 
studied. It was determined that as the W-256 cells left the lungs upon intravenous 
injections, cells began to arrive in the liver. However, less than 1.5% of the cells that 
arrived in the liver from the lungs survived and formed secondary tumours (metastases) 
[17]. Using a mouse model, B16F10 melanoma cells injected into the spleen were also 
used to study metastatic inefficiency. Approximately 20% of the cells injected into the 
spleen were observed in the liver microvasculature, followed by only 0.13% of these cells 
forming secondary metastases in the liver [16].
Others have also found evidence of metastatic inefficiency in mouse models. For 
example, the use of in vivo videomicroscopy showed that approximately 80% of cancer 
cells that were injected intraportally to target the mouse liver survived in the 
microcirculation and extravasated. However, only ~2% of cells survived and maintained 
micrometastases, and only ~0.02% of cells were able to sustain growth and develop into
macrometastases [15]. Other experimental studies have supported this data, including the 
injection of melanoma cells into the inferior vena cava to target the mouse lung, where it 
was observed the majority of the cells injected were able to survive in the 
microcirculation and extravásate, but less than 2% of the injected cells formed 
micrometastases (< 80 pm) and less than 6% of the injected cells formed 
macrometastases (> 300 pm). Interestingly, the reason why there were a higher 
percentage of injected cells that formed macrometastases when compared to the 
micrometastases was because Cameron, et al. observed that once the micrometastases had 
formed, their efficiency of progression of large secondary tumours was high [14].
The concept of metastatic ineffiency is also supported by clinical observations. A 
study by Tarin, et al. (1984) investigated the metastatic characteristics of 29 ovarian 
cancer patients (15 of which were autopsied and the pathology was determined) who 
underwent pertioneovenous shunting [20]. This shunting technique involved anastomosis, 
where the ascites fluid that contained the ovarian cancer cells were returned to the 
circulation of the patients via a one-way valve between the peritoneal cavity and the lungs 
in order to alleviate the pain. The results from the shunting technique suggested that 
metastatic inefficiency was occurring, where not all the ovarian cancer cells were able to 
initiate and maintain secondary metastases in every patient. In half of the patients, 
pulmonary metastases developed, but were not clinically relevant (no clinical symptoms). 
Many other cases did not show metastatic lesions up to 27 months later (the length of the 
study), even though the patients died from their original disease [20]. Thus, metastatic 
inefficiency has been observed in animal models and patient studies, suggesting that 
although most of the cancer cells that escape the primary tumour can survive in the
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circulation and extravásate, only a very small proportion of these cells are able to 
successfully form clinically relevant metastases at secondary sites.
Despite the small percentage of cancer cells from the primary tumour that are able 
to successfully metastasize, breast cancer metastasis remains a major contribution to 
cancer mortality in women due to the ineffectiveness of therapies in the metastatic setting 
[2-5]. It is therefore crucial to better understand the biology of metastasis so that we can 
develop more effective breast cancer therapies in the future. To date, the ability to 
identify and target the deadly subset of cancer cells that cause metastasis remains elusive. 
Our research group and others believe that these “metastasis-initiating cells” may in fact 
be cancer stem cells.
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2.4 Cancer Stem Cells
Growing evidence suggests that the cells responsible for initiating and maintaining 
cancer are in fact “cancer stem cells” (CSCs). Although the CSC hypothesis was first 
proposed approximately 150 years ago [21-23], technological advances in the area of rare 
cell identification and isolation have led to a resurgence of interest in this area, including 
in the field of breast cancer [2, 4, 24-30]. In the late 19th century, Cohnheim and Durante 
observed the similarity between embryonic tissue and cancer, and suggested that tumours 
arise from embryonic-like cells. They also suggested that adult tissues could contain a 
subset of embryonic cells that are generally dormant, but could also be activated to 
become tumourigenic [21, 22, 31]. Cancer stem cells are currently defined as cancer cells
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Figure 2. The cancer stem cell hypothesis is based on the hierarchy model 
of tumourigenesis. The two conflicting models of tumour development include 
the classic “stochastic model” (A) and the “hierarchy” model (B), where a 
mutagenic event (yellow lightning bolt) can occur to initiate the tumourigenic 
process. The stochastic model proposes that every cell within a tumour is 
potentially tumour-initiating, but progression to tumourigenic growth is 
governed by rare stochastic (or random) events. In contrast, the hierarchy model 
predicts that only a limited number of cells within the tumour are capable of 
initiating tumourigenic growth, but this subset of cells (pink) all initiate tumours 
at a high frequency, have the ability to recapitulate the heterogeneous tumour 
population, and have the capacity for self-renewal (curved arrows), thus giving 
rise to more of the same cells. Adapted from Dick, JE (2009) Nature 
Biotechnology, 27(1), 44-46.
within a heterogeneous tumour that have the capacity to self-renew (similar to normal 
stem cells, hence the nomenclature) and undergo differentiation to recapitulate the 
heterogeneous tumour population [2, 4, 32], It is important to note that the term “cancer 
stem cell” is still just that, a term or a nomenclature, since the cellular origin of the cancer 
stem cell remains the subject of intense investigation and debate.
Currently there are two conflicting models of tumour development {Figure 2)
[27, 33]. The classic “stochastic model” proposes that every cell within a tumour is 
potentially tumour-initiating, but progression to tumourigenic growth is governed by rare 
stochastic (or random) events. In contrast, the “hierarchical model” (upon which the CSC 
hypothesis is based) proposes that only a limited number of cells within the tumour are 
capable of initiating tumourigenic growth, but this subset of cells all initiate tumours at a 
high frequency. This supports the existence of a heterogeneous tumour population and the 
idea that tumourigenic mechanisms function differently in different subsets of cells [27, 
30, 33]. Currently, because cancer therapies are based on the stochastic model and not the 
hierarchical model, along with the fact that current therapies are non-curative in the 
metastatic setting, the hierarchical model on which the CSC hypothesis is based may be 
the more accurate model [27].
Cancer stem cells were first identified in acute myeloid leukemia (AML) by Dr. 
John Dick’s group in 1994. They observed that CD34+CD38' leukemia-initiating cells 
were able to engraft into severe combined immunodeficient (SCID) mice and recapitulate 
the original tumour population as seen in AML patients [34], CSCs have also been 
identified in several other cancer types, including various forms of leukemias as well as
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solid tumours of the breast, liver, pancreas, brain, colon, prostate, and other organs based 
on various surface antigens [30, 35-44].
Interestingly, many have suggested that perhaps the stochastic clonal evolution 
and hierarchical models of tumourigenesis are not mutually exclusive [45-48], with new 
evidence supporting this idea from John Dick’s group [46]. Using xenografting and DNA 
copy number alteration profiling of human acute lymphoblastic leukemia (ALL), Notta, et 
al. found that leukemia progression can occur in a linear fashion (as suggested by the 
hierarchical cancer stem cell hypothesis), or in a branching fashion, with various genetic 
subclones that evolve in succession or in parallel, respectively. The dominant aggressive 
leukemic clones that are associated with poor outcome appear to be leukemia-initiating 
cells, and they sustain the minor, initially non-dominant subclones. Some of these minor 
subclones can then survive the therapy and become aggressive after the recurrence of 
leukemia. This is perhaps due to additional stochastic or non-stochastic genetic or 
epigenetic events that are required for increased aggressiveness [46]. Whether the cancer 
stem cell hypothesis is based on the stochastic, hierarchical, or a hybrid of the two, the 
important point is that there is growing evidence that CSCs exist and that they are a 
subpopulation of cells that are highly tumourigeneic and have the capacity to self-renew 
and recapitulate the heterogeneous tumour population. These CSCs in the breast are
discussed in detail below.
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2.5 Breast Cancer Stem Cells
2.5.1 CD44+CD24' Breast Cancer Cells
The existence of CSCs or tumour-initiating cells in solid cancers was first 
demonstrated by Al-Hajj, et al. (2003) via the identification and isolation of these cells 
from breast cancer patient primary tumours and pleural effusions based on a CD44+CD24' 
phenotype [30]. The in vivo tumour-initiating capacity of CD44+CD24' breast cancer cells 
was tested, and it was observed that injection of as few as 100 CD44+CD24' into the 
mammary fat pad of non-obese diabetic (NOD)/SCID mice resulted in tumour formation. 
In contrast, injection of up to 20,000 or 100,000 CD44+CD24+ breast cancer cells from 
cell lines or patient samples into NOD/SCID mice, respectively, did not result in the 
formation of tumours. The authors concluded that CD44+CD24' breast cancer stem-like 
cells are tumourigenic and are highly efficient at initiating breast cancer compared to the 
heterogeneous population of breast cancer cells [30],
Subsequent studies have shown that CD44+CD24' breast cancer cells display 
characteristics of normal stem cells as well as aggressive cancer cells, including increased 
expression of stem cell markers; the ability to self-renew; an enhanced capacity for in 
vitro mammosphere formation and invasion; expression of higher levels of anti-apoptotic 
proteins; and the ability to recapitulate a heterogeneous tumour population in vivo [30, 
49-52], Additionally, clinical studies have shown that CD44+CD24‘breast cancer cells 
express an invasive gene signature [53] and are associated with aggressive basal-like 
(triple-negative) disease [54] and secondary metastases [55, 56].
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CD44 and CD24 are adhesion molecules, where CD24 is mainly expressed on B- 
cells (except plasma cells) and plays a co-stimulatory role between B-cells and T-cells 
[29, 57], while CD44 is expressed on a wide range of cells such as leukocytes, 
erythrocytes, haematopoietic stem cells, epithelial and endothelial cells [57]. CD44 is 
part of a family of transmembrane glycoproteins that act as cell-cell or cell-matrix 
adhesion proteins and play many roles in normal cells such as cellular mobilization and 
homing [29, 58, 59], adhesion, migration, proliferation, and signalling. CD44 is a receptor 
for hyaluronan and other extraceullar matrices [57, 59, 60]. Because of the roles that 
CD44 plays in normal cell migration, adhesion, and proliferation, it is not surprising that 
CD44 also plays an important role in cancer and metastatic behaviour. In fact, with the 
interactions that CD44 has with other ligands, CD44 is not only an adhesion molecule 
that facilitates motility, but also modulates matrix degradation, proliferation, and cell 
survival, all of which help the cancer cell to complete the metastatic cascade [59, 61].
2.5.2 Breast Cancer Stem Cells with High Aldehyde Dehydrogenase Activity 
(ALDHhi)
The activity of aldehyde dehydrogenase (ALDH) has also been shown to be a 
reliable identifier of CSCs in several types of solid tumours [62-64] including breast 
cancer [29, 65, 66], ALDH is an intracellular detoxification enzyme that also plays a role 
in the metabolism of biogenic amines, corticosteroids, and the conversion of retinal 
(retinaldehyde) to retinoic acid [67-69]. Retinoic acid plays an important role in 
mammalian development and cellular homeostasis, in addition to having a protective role
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in both normal stem cells and cancer cells [67-69]. It has been shown that high activity of 
ALDH is characteristic of haematopoietic stem cells (HSCs) [70], and Ginestier et al. 
(2007) demonstrated that ALDH activity is also a marker of normal and malignant human 
mammary stem cells [66], They observed that when 50,000 ALDHlow breast cancer cells 
were transplanted into cleared mammary fat pads of NOD/SCID mice, no tumour was 
formed, but when as few as 500 ALDHhl cells were injected, tumours formed in 40 days, 
suggesting that ALDHhl breast cancer cells are highly tumourigenic [66]. Importantly, 
expression of ALDH1 in primary tumour tissue was also associated with poor prognosis 
in breast cancer patients [65, 66, 71].
Previous work in our lab has demonstrated that stem-like breast cancer cells can 
be isolated from human breast cancer cell lines based on the combination ALDHhlCD44+ 
phenotype, and that these cells show significantly increased malignant and metastatic 
behaviour in vitro and in vivo relative to ALDHlowCD44' cells [7]. We found that when 
the metastatic breast cancer cell lines MDA-MB-468 and MDA-MB-231 were sorted into 
ALDHhlCD44+ and ALDHlowCD44‘ populations using fluorescence activated cell sorting 
(FACS), and were subjected to in vitro assays of metastasis, the ALDHhlCD44+ cells 
displayed significantly enhanced metastatic behaviour (proliferation, migration, adhesion, 
invasion, colony formation) relative to the ALDHlowCD44‘cells [7], Additionally, 
ALDHhlCD44+ cells from both cell lines also displayed enhanced metastatic growth in 
vivo that resulted in significant increases in metastatic incidence and metastatic burden in 
the lungs. This was observed in both experimental (tail-vein injection) as well as 
spontaneous (mammary fat pad injection) models of metastasis using NOD/SCID/IL-2Ry 
(interleukin-2 receptor gamma) null mice [7]. Our metastasis study was also supported by
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a study by Charafe-Jauffret, et al. (2010) that investigated the role ALDH has on 
inflammatory breast cancer [72]. They found that the inflammatory breast cancer cell line, 
SUM 149, had a subpopulation that was ALDHhlCD44+CD24'. Upon sorting the ALDHhl 
cells from the ALDHlow SUM 149 cells, in vitro assays of invasion and in vivo assays of 
métastasés were performed. ALDHhl SUM 149 cells had a significantly higher capacity to 
invade in a Matrigel assay than the ALDHlovv cells. Using a non-invasive photon flux to 
image luciferase bioluminescence, metastasis was assessed in NOD/SCID mice that were 
injected via an intracardiac route with 50,000 and 100,000 ALDHhl, ALDHlow or unsorted 
SUM 149 populations. Histological sections of the bone and liver were used to confirm 
métastasés and it was observed that no ALDHlow cells were able to form secondary 
métastasés, while ALDHhl and unsorted cells could [72]. Thus studies from our lab as 
well as others suggest that ALDH activity can identify metastasis-initiating cells and may 
play a role in breast cancer metastasis.
The role of ALDH as a detoxifying enzyme suggests that high ALDH activity in 
cancer cells may also play a role in conferring resistance to cancer therapies [29, 65, 71]. 
Although extensive literature has shown that high ALDH activity confers resistance to 
alkylating agents such as cyclophosphamide and other oxazaphosphorines [70, 71, 73- 
88], the role that ALDH plays in other types of chemotherapy (such as taxanes and 
anthracyclines) and/or radiation resistance hasu not been well studied, especially in breast 
cancer. In 2009, a group in Japan identified breast CSCs in over 100 breast cancer 
patients undergoing neoadjuvant chemotherapy (paclitaxel and epirubicin) using the 
ALDHhl and CD44+CD24‘ phenotypes, and observed that ALDHhl tumour cells increased 
significantly after neoadjuvant chemotherapy, whereas CD44+CD24‘ cells did not [65],
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Recently, our lab published some very exciting and novel results supporting the role that 
ALDH plays in chemotherapy and radiation resistance in breast cancer. Our results 
indicate that the inhibition of ALDH activity, whether by using 
diethylaminobenzaldehyde (DEAB) or all-trans retinoic acid (ATRA), results in 
sensitization of ALDHhlCD44+ human breast cancer cells to standard chemotherapy 
(doxorubicin/paclitaxel) and radiation [6]. Our study showed that significantly more 
ALDHhlCD44+ breast cancer cells survived chemotherapy or radiation when compared to 
the ALDHlowCD44' cells. Pre-treatment with either DEAB or ATRA to inhibit ALDH 
activity resulted in a significant sensitization to chemotherapy/radiation for the 
ALDHhlCD44+ cells, but only the direct ALDH inhibitor DEAB had a long term effect, 
and thus was more effective for use as a combination treatment for targeting 
ALDHhlCD44+ breast cancer cells [6], Additionally, through the conversion of retinal to 
retinoic acid, there is also evidence that ALDH can influence early differentiation in some 
types of stem cells [66, 89, 90]. When we treated the ALDHhlCD44+ breast cancer stem­
like cells with ATRA, cytokeratins (CK) 8/18/19 [a marker of differentiation/epithelial- 
mesenchymal transition (EMT)] significantly increased, suggesting that down-regulation 
of ALDH activity via ATRA treatment can influence differentiation in ALDHhlCD44+ 
breast cancer cells [6], Thus ALDH activity may play a protective role in stem-like breast 
cancer cells by conferring drug resistance and/or influencing differentiation.
Breast cancer stem cells can be identified by the CD44+CD24‘ phenotype, and/or 
by high ALDH activity [29, 30, 35-44, 62-66]. Although there is a lot known about the 
functional roles of CD44 in breast cancer metastasis, more studies are needed to elucidate
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and expand the knowledge of the functional role of ALDH in this process. Thus the main 
focus of this thesis will be on the enzyme aldehyde dehydrogenase (ALDH).
2.6 Aldehyde Dehydrogenase
2.6.1 The Human ALDH Superfamily
The human aldehyde dehydrogenase (ALDH) superfamily currently consists of 19 
known putatively functional genes [91-93] in 11 families and 4 subfamilies [93] with 
distinct chromosomal locations {Table 1). When compared to the human genome, the rat 
and mouse genome has an additional ALDH gene {Aldhlal). Although many mammalian 
ALDH genes have been identified, as well as various alternatively spliced transcriptional 
variants of human ALDH genes, several of the corresponding proteins have not been fully 
characterized [93] and can potentially be a vast area of exploration for researchers.
The ALDH enzymes can be found in the cytosol, nucleus, mitochrondria, or 
endoplasmic reticulum [91,94], Depending on the enzyme family and subfamily, the 
human ALDHs can vary in their enzyme levels, as well as in their tissue and organ 
distribution [94-96]. The ALDH superfamily of NAD(P)+-dependent multifunctional 
enzymes catalyze the oxidation of various endogenous and exogenous aldehydes to their 
corresponding carboxylic acids (Figure 3) [91-93, 97], Aldehydes are highly reactive 
electrophilic compounds that have a long lifespan, and can play a vital role in 
physiological processes as well as playing mutagenic, carcinogenic, and cytotoxic 
detrimental roles [91,92], Endogenous aldehydes can be generated by various metabolic 
processes, including lipid peroxidation, amino acid catabolism, biotransformation of
17














L iv e r ,  k id n e y , re d  b lo o d  c e l ls  (R B C s ) ,
ALDH1A1 C y to s o l A L D H  1 A l  v 2 s k e le ta l  m u s c le ,  lu n g , b re a s t ,  le n s , s to m a c h  m u c o s a ,  b ra in ,  p a n c re a s ,  te s t is . P e r h a p s  a lc o h o l i s m
p ro s ta te ,  o v a ry
A L D H 1 A 2  v2
ALDHIA2 C y to s o l A L D I 11A 2  v3 T e s t is ,  s m a ll  a m o u n ts  in  l iv e r , k id n e y S p in a  b i f id a
A L D H 1 A 2  v4
ALDH1A3 C y to s o l A L D H  1 A 3  v2 K id n e y ,  s k e le ta l  m u s c le ,  lu n g ,  b re a s t ,  t e s t i s ,  s to m a c h  m u c o s a ,  s a l iv a ry  g la n d s
ALDHIB1 M ito c h o n d r ia - L iv e r ,  k id n e y ,  h e a r t ,  s k e le ta l  m u s c le ,  b r a in ,  p ro s ta te ,  lu n g , te s t i s ,  p la c e n ta V a r io u s  p h e n o ty p e s
ALDHIL1 C y to s o l - L iv e r , s k e le ta l  m u s c le ,  k id n e y
ALDHIL2 U n k n o w n A L D I H L 2  v2  A L D I H L 2  v3
ALDH2 M ito c h o n d r ia L iv e r ,  k id n e y ,  h e a r t ,  s k e le ta l  m u s c le . E th a n o l- in d u c e dle n s ,  b ra in ,  p a n c re a s ,  p ro s ta te ,  s p le e n c a n c e r s ,  h y p e r te n s io n
A L D I I3A 1  v2  
A L D H 3 A 1  v3
ALDH3A1 C y to s o l .n u c le u s
A L D H 3 A 1  v 4  
A L D H 3 A I  v5 
A L D H 3 A 1  v 6  
A L D I I3A 1  v 7
S to m a c h  m u c o s a ,  c o rn e a ,  b re a s t ,  lu n g , 
le n s ,  e s o p h a g u s ,  s a l iv a ry  g la n d s ,  sk in V a r io u s  p h e n o ty p e s
A L D H 3 A 2  v2
ALDH3A2 M ic ro s o m e s ,p e r o x is o m e s
A L D H 3 A 2  v3 
A L D H 3 A 2  v4  
A L D H 3 A 2  v5  
A L D I I3 A 2  v 6  
A L D H 3 B I  v2
L iv e r ,  k id n e y ,  h e a r t ,  s k e le ta l  m u s c le ,  
lu n g ,  b r a in ,  p a n c re a s ,  p la c e n ta ,  m o s t  
t i s s u e s
S jo g re n -L a r s s o n
s y n d ro m e
ALDH3BI C y to s o l A L D H 3 B I  v3 A L D I 13131 v 4  
A L D H 3 B I  v5
K id n e y , lu n g , p a n c re a s ,  p la c e n ta
ALDH3B2 U n k n o w n A L D H 3 B 2  v2  A L D H 3 B 2  v3 
A L D H 4 A 1  v2
P a ro t id  g la n d
ALDH4AI M ito c h o n d r ia A L D H 4 A 1  v3 L iv e r ,  k id n e y ,  h e a r t ,  s k e le ta l  m u s c le . T ype  IIA L D H 4 A I  v 4  
A L D I 14A1 v5
b r a in ,  p la c e n ta ,  lu n g , p a n c re a s ,  s p le e n h y p e r p r o l in c m ia
ALDH5A1 M ito c h o n d r ia A L D H 5 A 1  v2  A L D H 5 A 1  v3  
A L D H 6 A 1  v2
L iv e r ,  k id n e y , h e a r t ,  s k e le ta l  m u s c le ,  
b ra in
L -h y d ro x y b u ty r ic
a c id u r ia
ALDH6A1 M ito c h o n d r ia A L D H 6 A 1  v3 
A L D I I6A 1 v 4
L iv e r ,  k id n e y , h e a r t ,  s k e le ta l  m u s c le D e v e lo p m e n ta l  d e la y
ALDH7AI
C y to s o l .
n u c le u s ,
m i to c h o n d r ia
-
F e ta l  l iv e r , k id n e y , h e a r t ,  lu n g , b ra in ,  
o v a ry ,  e y e , c o c h le a ,  s p le e n ,  a d u l t  s p in a l  
c o rd
P y r id o x in e - d e p c n d c n t
e p i le p s y
ALDH8A1 C y to s o l A L D I I 8 A 1 v2 L iv e r ,  k id n e y ,  b ra in ,  b re a s t ,  t e s t i s
L iv e r ,  k id n e y ,  h e a r t ,  s k e le ta l  m u s c le .
ALDH9AI C y to s o l - b ra in ,  p a n c re a s ,  a d re n a l  g la n d , s p in a l V a r io u s  p h e n o ty p e s
c o rd
ALDH16A1 l I n k n o w n A L D H 1 6 A 1  v2 N e u r o n a l  c e l ls  |9 8 |
ALDHI8AI M ito c h o n d r ia A L D I 11 8 A  l_ v 2 K id n e y ,  h e a r t ,  s k e le ta l  m u s c le ,  p a n c re a s ,  t e s t i s ,  p r o s ta te ,  s p le e n ,  o v a ry ,  th y m u s












Figure 3. The role of aldehdye dehydrogenase (ALDH) in retinoic acid synthesis.
Alcohols such as retinol are first reversibly oxidized by alcohol dehydrogenase (ADH) 
into aldehydes such as retinaldehydes (retinal). Aldehydes such as retinal can then be 
irreversibly oxidized into carboxylic acids such as retinoic acid (RA) by aldehyde 
dehydrogenase 1 (ALDH1). Retinoic acid (RA) can then bind to the retinoic acid 
receptor (RAR) to result in gene expression and cell differentiation. ALDH1 is under 
the regulation of a negative feedback mechanism, where when there is an increase in 
intrinsic RA, RA will negatively feedback to inhibit ALDH1 expression (see Figure 
5). Adapted from Marchitti, el al. (2008), Expert. Opin. Drug. Metab. T oxico l4(6): 
697-720.
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neurotransmitters and carbohydrates [91]; as well as through metabolism of vitamins 
(retinal to retinoic acid [68]) and steroids [92. 93], The source of exogenous aldehydes 
includes the biotransformation of exogenous aldehyde precursors such as xenobiotics and 
drugs (i.e. ethanol, cyclophosphamide, ifosfamide); as well as environmental aldehydes 
that are present in industrial applications such as smog, cigarette smoke, and motor 
vehicle exhaust [91]. In addition to the oxidization of aldehydes, other catalytic functions 
of the human ALDH superfamily of enzymes include ester hydrolysis (ALDH1A1, 
ALDH2, ALDH4A1) and nitrate reductase activity (ALDH2) [91, 92]. Some enzymes of 
the ALDH superfamily also have the capacity for non-catalytic functions, including being 
able to bind to endobiotics (ALDH1A1) and xenobiotics (ALDH1A1, ALDH1L1, 
ALDH2), having antioxidant functionalities (ALDH1 Al, ALDH3A1). having structural 
roles (ALDH1A1, ALDH3A1), and being involved in osmoregulation (ALDH7A1) [91, 
92],
Of the vast ALDH families and subfamilies, it has been shown that the ALDH 
enzymes that are involved in the function of normal stem cells as well as cancer stem 
cells include the ALDH 1 family (ALDH 1A1. 1A2, 1A3, 1L1, 1L2), ALDH2*2 (with an 
association between alcoholism and alcohol-induced cancer risk), ALDH3A1 (highly 
protective for normal stem cells and cancer cells, with a role in hormone-dependent 
tumours), ALDH4A1 (through p53 and DNA damage), and ALDH7A1 (putatively 
involved in the regulation of cell cycle) [91], all of which are found in various 
chromosomal locations [96],
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2.6.2 ALDH as a Marker for Cancer Stem Cells
As discussed earlier, the activity of intracellular ALDH has also been shown to be 
a reliable marker of CSCs in several types of solid tumours, including tumours of the 
breast, head and neck, lung, liver, pancreas, cervix, ovary, prostate, colon, and bladder 
[29. 42, 43, 62, 64-66, 99-108], It has also been shown that high expression of ALDH1 is 
associated with poor prognosis in breast, bladder and prostate cancer patients [65, 66, 71, 
104-106], In a study of 577 breast cancer patients, it was shown that patients with 
ALDH 1-positive tumours had a lower overall survival compared to patients with ALDH- 
low tumours [66], Similarly, in two independent studies analyzing 163 and 269 primary 
prostate cancer patient samples (respectively), it was shown that patients with high 
ALDH1A1 expression correlated with lower overall survival [104, 105], Gleason score, 
and pathologic stage [104], Furthermore, it has been observed that ALDH activity is a 
marker of normal and malignant human mammary stem cells [66], as well as normal and 
malignant human colon stem cells [64], It has also been observed that CSCs in adenoid 
cystic carcinoma [107], prostate cancer [104, 108], head and neck squamous cell 
carcinoma [102], lung cancer [62], pancreatic adenocarcinoma [105], cervical carcinoma 
[99], and bladder cancer [106] with high ALDH activity have enhanced tumourigenicity 
and stem cell characteristics in vitro and in vivo compared to cells with low ALDH 
activity. Other groups have found that breast, bladder, and prostate CSCs with a high 
ALDH activity appear to display more aggressive characteristics, may mediate metastasis, 
and/or are associated with a poor prognosis in cancer patients [7, 66, 72, 105, 106, 108],
ALDH may not be a suitable CSC marker for all tumour types. A recent study 
investigated the patterns and levels of ALDH1 expression in 24 types of normal human
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tissue as well as primary epithelial tumour specimens and epithelial cancer cell lines 
[103]. From this study, it was determined that ALDH1-positive cells can be clearly 
identified in regions where epithelial stem/progenitor cells are putatively located. 
Furthermore, it was observed that ALDH1 distribution patterns in normal tissues were 
distinct, and were classified into three types: 1) tissues with absent or limited ALDH1 
expression (i.e. breast and lung); 2) tissue with relatively weak ALDH1 expression (i.e. 
colon and gastric epitheliums); and 3) tissue with extensive and high ALDH1 expression 
(i.e. liver and pancreas). Thus, the authors concluded that ALDH1 can be effectively used 
as a CSC marker in tissue types that normally do not express ALDH1 at a high level 
(such as breast, lung, colon and gastric epitheliums), but should not be used as a CSC 
marker in tissue types that normally express a high level of ALDH1 (such as liver and 
pancreas) [103],
2.6.3 ALDH Distribution in Normal and Malignant Breast Tissue
The aggressiveness of breast cancers has been shown to correlate with their 
ALDF1 activity. For example, basal-like, basal/epithelial and HER2+ breast cancer cell 
lines have been observed to contain relatively more ALDHhl cells when compared to 
more luminal breast cancer cell lines such as MCF-7, T47D [109], Additionally, high 
ALDH activity and/or expression in breast tumours has been shown to be correlated with 
poor prognosis [66],
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2.6.4 Experimental Tools Used to Identify and Isolate ALDHhl Cells
A common experimental tool that people use to identify ALDHhl cells are specific 
antibodies against ALDH to stain in tissue sections from patient samples, animal models, 
or in cell lines. Many have used ALDH1 or ALDH1A1 antibodies for 
immunohistochemistry to stain for expression in human breast tissue samples to 
determine the distribution of markers and prognosis of these patients [66, 72, 109, 110]. 
Although this tool is useful in determining the expression of ALDH1 in tissues and cells, 
immunohistochemistry cannot determine the enzyme activity of ALDH1 in the cells of 
these tissues or cell lines.
Traditionally, a method that many researchers use to identify ALDH activity in 
cells is the spectrophotometric based method, where cells are lysed to release the 
intracellular enzymes, followed by measuring the rate of change in absorbance at 340 nm 
due to the colour change from the conversion of a proprionaldehyde substrate into 
carboxylic acid by the enzyme [62, 76, 79, 80, 111, 112]. Depending on the mechanistic 
actions of the enzyme, NAD+ as well as other substrates are also added to facilitate 
enzymatic activity. However, a major disadvantage in measuring enzymatic activity this 
way is the requirement of lysis of the cells to release intracellular enzymes. This assay 
would not be useful for studies that require the analysis of ALDH activity in live cells.
A decade and a half ago, Jones, el al. reported for the first time that intracellular 
ALDH activity could be measured in viable cells. They found that dansyl 
aminoacetaldehyde (DAAA), a fluorescent aldehyde, could be used in flow cytometry to 
isolate and enrich for viable human haematopoietic stem cells (HSCs) and leukemic stem
cells (mouse and human) based on their ALDH activity [113]. Hydrophobic DAAA can 
diffuse freely across cell membranes, so cells with ALDH activity can oxidize DAAA 
into dansyl glycine. Dansyl glycine is negatively charged at the physiological pH, and 
therefore is not able to exit the cells, thus causing the cells with dansyl glycine to become 
fluorescent [113]. As a negative control, cells were also incubated with 4- 
(diethylamino)benzaldehyde (DEAB), a specific ALDH inhibitor [113, 114], Jones, et al. 
hypothesized that there were advantages to using a technique that could detect ALDH 
activity levels within viable cells. The main advantage is that having a method that could 
also isolate viable tumour cells that are resistant to alkylating agents such as 
cyclophosphamide and express high levels of ALDH could be beneficial for studying 
drug resistance in tumour cells [113]. Unfortunately, there were some drawbacks to this 
technique [69], The DAAA fluorescence was excited by UV emissions, which could be 
mutagenic for cells that would be isolated and used for downstream applications. In 
addition, the emission spectra of DAAA overlapped with other fluorochromes, making 
this technique difficult to combine with analysis of other stem cell markers [69, 113],
Four years after the Jones et al. publication, Storms et al. developed a more 
straightforward and efficient strategy for isolating primitive HSCs using the fluorescent 
substrate boron-dipyrromethene (BOD1PY) aminoacetaldehyde (BAAA) [69] (more 
commonly known now as the Aldefluor® Assay) that is used to isolate and identify 
cancer stem-like cells as well as HSCs [4, 64, 66, 90, 115]. The BAAA strategy is similar 
to the DAAA one in that cells with high levels of ALDH activity will uptake the 
uncharged ALDH substrate BAAA by passive diffusion and then convert BAAA into 
negatively-charged BODIPY-aminoacetate (BAA‘). BAA' is then retained inside cells,
causing the subset of cells with a high ALDH activity (ALDHhl) to become highly 
fluorescent. As a negative control, DEAB, a specific ALDH inhibitor, is used to quench 
the activity of ALDH-positive cells [4, 69] (Figure 4). We and others in the cancer stem 
cell field [4, 66] have defined ALDHhl or ALDH+ as a subset of the population that 
express a high ALDH activity, which can be determined by the criteria of the sorting 
gates. Populations in the top 10-20% are considered ALDHhl, whereas populations in the 
bottom 10-20% are considered ALDHlovv. These ALDHhl populations can be distinguished 
easily by setting the gates based on the DEAB negative control [4, 66]. Currently, the 
Aldefluor® assay is being used in various human models [6, 7, 66, 90, 116],
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2.6.5 ALDH1 and the Retinoid Signalling Pathway
Retinoid signalling pathways have been implicated in cancer [78, 79, 117, 118], 
Retinoic acid (RA) and its derivatives are involved in many critical physiological 
processes, including the regulation of gene expression, morphogenesis and development 
[67, 119, 120]. The four distinct families of retinoid dehydrogenases that convert retinol 
(vitamin A) to RA are alcohol dehydrogenase (ADH), short-chain dehydrogenase/ 
reductase, aldo-keto reductase, and ALDH1 [119]. Retinol is first oxidized by ADH to 
retinaldehyde, and this process is reversible. Retinaldehyde is then irreversibly oxidized 
to RA by cytosolic ALDH1 (human ALDH1 Al, ALDH1A2, ALDH 1 A3). The latter 
reaction is a tightly regulated process that is tissue-specific, since the oxidation of 
retinaldehyde to RA is an irreversible reaction, with RA having a potent biological
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Figure 4. The Aldefluor® Assay. To assess ALDH activity, cells can be labelled 
using the ALDEFLUOR® Assay Kit (StemCell Technologies, Vancouver, BC) as per 
the manufacturer’s protocol. ALDH-positive cells {right) will uptake uncharged 
ALDH substrate (BODIPY-aminoacetaldehyde [BAAA]) by passive diffusion and 
then convert BAAA into negatively-charged BODIPY-aminoacetate (BAA ). BAA" is 
then retained inside cells, causing the subset of ALDHhl cells to become highly 
fluorescent. The addition of cold assay buffer (as provided by the manufacturer) 
prevents the ATP-binding cassette (ABC) transporters from pumping the BAA- 
substrate out of the cells. As a negative control {left), diethylaminobenzaldehyde 
(DLAB), a specific ALDH inhibitor, is used to quench the activity of ALDHhl cells, 
preventing the cells to become fluorescent. Figure adapted from Ma and Allan (2010), 
Stem Cell Reviews and Reports, 7(2): 292-306.
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activity {Figure 3 and 5) [91, 119], The resulting RA produced can then act on nuclear 
retinoic acid receptor (RAR)-a, p, y. and retinoid X receptor (RXR)-a, p, y, which bind 
DNA as heterodimers and result in the regulation of gene expression and cell 
differentiation [119, 121], The RARs bind &\\-trans-RA (ATRA) and 9-clv-RA, while the 
RXRs bind only the 9-c/.v-RA. Once RA has been synthesized, the RA signalling pathway 
initiates, whereas the degradation of RA or the cessation of RA synthesis stops RA 
signalling [119], Murine retinaldehyde dehydrogenase 1 (Raldhl) has similar tissue- 
specificity and developmental control as the cytosolic human ALDH1 [121], Studies by 
Elizondo, et al. in 2000 and 2009 demonstrated that mouse Raldhl transcription is under 
the regulation of a negative feedback mechanism [68, 121], When there are low 
intracellular RA concentrations, RARa and CCAAT/enhancer-binding protein (C/EBPP) 
transactivates the Raldhl promoter, thereby increasing the Raldhl activity to increase the 
oxidization of retinaldehyde to retinoic acid. As RA levels increase, C/EBPp mRNA 
increases, which also increases GADDI 53 mRNA. A complex of GADDI53 and C/EBPp 
then forms to decrease DNA binding activity of C/EBPP to the CCAAT box of the 
Raldhl promoter, thereby inhibiting the transactivation of Raldhl. This ultimately results 
in a decrease in RA synthesis [68, 121] {Figure 5).
2.6.6 Role of ALDH in Differentiation
Retinoic acids such as ATRA are commonly used as differentiation agents in stem 
cell research [90, 122-125], and have been used to induce remission in acute 
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Figure 5. ALDH1 is under the negative feedback regulation of retinoic acid.
(A) Retinol is first reversibly oxidized by alcohol dehydrogenase (ADH) into 
retinaldchyde, where it can then be irreversibly oxidized into retinoic acid (RA) by 
aldehyde dehydrogenase (ALDH1). RA can then bind to the retinoic acid receptor 
(RAR) to result in gene expression and cell differentiation. ALDH1 is under the 
regulation of a negative feedback mechanism. When endogenous RA concentrations 
are low (B ), the RAR binds to the retinoic acid response element (RARE), and the 
CCAAT/enhancer-binding protein-P (C/EBPP) binds to the CCAAT box. Together, 
the RAR and C/EBPp transactivate the Aldhl promoter, and activates transcription. 
As ALDH1 levels increase, this can result in an increase in RA synthesis, as well as 
cellular protection against cytotoxic drugs. (C) Conversely, when intracellular RA is 
high, C/EBPp increases, which then forms a complex with GADDI53. The 
C/EBPp GADDI53 complex then decreases the DNA binding activity of C/EBPp 
to the CCAAT box of the Aldhl promoter, thereby inhibiting the transactivation of 
Aldhl. This results in a decrease in RA synthesis, as well as cellular sensitivity to 
drugs. Figure adapted from Ma and Allan (2010), Stem Cell Reviews and Reports. 
7(2): 292-306.
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leukemic cells into neutrophils [117]. It has also been shown in vivo that ALDH1A1 
promotes myeloid differentiation in murine haematopoietic stem cells (HSCs) [126], In 
murine and human in vitro models, inhibition of ALDH1 using DEAB or siRNA resulted 
in HSC differentiation and a decrease in cEBPc (an RAR-specific response gene), thus 
reducing intrinsic retinoic acid [90, 127]. When ATRA was added to DEAB-treated 
HSCs, differentiation and lineage commitment was promoted in HSCs [90],
Due to the negative feedback mechanisms of ALDH1 and retinoid signalling, one 
could hypothesize that treating CSCs that have high ALDH1 activity (relative to their 
normal tissue counterparts) with ATRA could potentially shift the CSCs into a more 
differentiated state, thereby making them less aggressive. Using a GSEA (gene set 
enrichment analysis) algorithm, Ginestier et al. were able to show that when various 
breast cancer cell lines were treated with ATRA, the genes that were downregulated were 
associated with pathways related to stem cell self-renewal programs, wingless/integration 
(WNT) signalling, AKT/(3-catenin signalling, the carcinogenesis process, metastatic 
activity, and drug resistance [118], The results of their study also suggest that ATRA 
treatment may induce breast CSC differentiation and decrease the CSC population. 
Conversely, genes that were overexpressed in DEAB-treated breast cancer cell lines were 
involved in tRNA biosynthesis, which is essential for protein synthesis and cell viability 
[118]. Similarly, results from our laboratory suggests that treatment of breast CSCs with 
ATRA results in an induction of expression of CK8/18/19, a differentiation/EMT marker 
[6], thus potentially making the CSCs less aggressive [6, 128],
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2.6.7 Role of ALDH in Cellular Self-Protection
Given the reported functions of ALDH enzymes, it is not surprising that ALDHs 
are generally regarded as detoxification enzymes that are critical for protecting organisms 
against various aldehydes that would be otherwise be harmful to them [91, 92, 97]. This 
fact is supported by growing evidence that deficiencies and polymorphisms of various 
ALDH enzymes can lead to clinical phenotypes and diseases [91, 94, 97], Some examples 
of these metabolic syndromes and diseases include spina bifida (ALDH1A2) [129], 
ethanol-induced cancers [130] and hypertension (ALDH2) [131], Sjogren-Larsson 
syndrome (ALDH3A2) [132], type II hyperprolinemia (ALDH4A1) [133],, y- 
hydroxybutyric aciduria (ALDH5A1) [134], and pyridoxine-dependent epilepsy 
(ALDH7A1) [135] (reviewed in detail in [91,94, 97], and in Table 1).
It has been widely observed that high cytosolic ALDH1A1 or ALDH3A1 activity 
in normal cells [73, 85], stem cells [136], and cancer stem cells [44, 65] confers resistance 
to therapy in preclinical model systems. However, the majority of these studies focused 
on alkylating agents such as cyclophosphamides and other oxazaphosphorines [70, 71, 
73-88], Cytosolic ALDH1A1 and ALDH3A1 are able to convert activated 
cyclophosphamide, 4-hydroxycyclophosphamide (4-HC), to the inactive excretory 
product carboxyphosphamide [70, 77], Clinically, 4-HC has been used to purge resident 
tumour cells ex vivo and treat autologous bone marrow transplantation [77], It was first 
observed over two decades ago that leukemic stem cells with a high ALDH activity were 
highly resistant to cyclophosphamide [75]. Only recently has it been shown that ALDH 
activity can also offer drug protection in stem-like cancer cells. Tanei et al. identified 
ALDH1+ and/or CD44+CD24‘ cells in over 100 breast cancer patients undergoing 
neoadjuvant chemotherapy consisting of paclitaxel and epirubicin. They observed that the
30
proportion of ALDH1-positive tumour cells and ALDH1 expression significantly 
increased after neoadjuvant chemotherapy, whereas the proportion of CD44+CD24" cells 
did not, suggesting that the high ALDH1 phenotype is a better predictive marker for 
chemotherapy resistance compared to CD44+CD24‘. Furthermore, it was observed that 
there was a significant association between ALDHhlgh breast cancer tumours and 
resistance to neoadjuvant chemotherapy with significantly lower pathologic complete 
response rates compared to ALDHnesatlve breast tumours [65], In addition to ALDH1, the 
estrogen receptor (ER) and Ki67 status are mutually independent predictors of 
chemotherapy (paclitaxel and epirubicin) response, therefore it may be wise to study ER 
and Ki67 status along with ALDH1 to predict a patient’s chemotherapy response more 
accurately [65, 110].
Recently, our lab has further expanded our current knowledge on the diverse roles 
ALDH has on cancer stem-like cell protection. This year, we were the first to link the role 
of ALDH activity inhibition (either directly using DEAB or indirectly using ATRA) to 
radiation sensitivity, as well as sensitivity to non-alkyating chemotherapies [6], Due to the 
detoxification roles that ALDH plays, we found that ALDHhlCD44+ cells were 
intrinsically more resistant to chemotherapy or radiation than ALDHlowCD44‘ cells, as 
expected. Conversely, ALDHlovvCD44" cells were extremely sensitive to both treatments. 
Upon inhibition of ALDH activity using DEAB, or sensitizing the ALDHh'CD44+ breast 
cancer cells using ATRA to influence differentiation, our lab has uncovered that ALDH 
plays a role in chemotherapy and radiation resistance. Importantly, we also found that 
specific inhibition of ALDH by DEAB was more effective at sensitising breast cancer
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stem-like cells to chemotherapy and/or radiation long term when compared to indirect 
inhibition of ALDH by ATRA, suggesting the importance of directly targeting ALDH [6],
Other studies have linked high ALDH1 expression to radiation sensitivity in other 
cancers [127, 137], By studying radiation-sensitive versus radiation-resistant cervical 
carcinoma specimens, Kitahara et al. observed that ALDH1 gene expression was 
significantly upregulated in the complete response group when compared to the non- 
responsive group. They concluded that in radiosensitive cervical cancer cells, the high 
ALDH1 expression level also increased the synthesis of retinoic acid (RA), which 
induced tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and 
apoptosis of the cancer cells after radiation. When cervical carcinoma cells were treated 
with RA before radiation, these cells became radiosensitive [137], If the cervical 
carcinoma cells that showed high expression of ALDH1 were CSCs, perhaps another 
reason for the radiosensitivity was due to the differentiation of these CSCs upon 
biosynthesis of RA [118], although the authors did not mention the CSC hypothesis in 
their study. Similarly, it has been observed that inhibition of ALDH1 expression in HSCs 
via siRNA or DEAB results in delayed differentiation due to the impairment of retinoid 
signalling, expansion, and radiation resistance [127]. It is likely that the scenario upon 
which different types of normal or cancer stem-like cells are resistant versus sensitive to 
radiation may be species- and/or tissue-specific. Thus, further research is needed to 
clarify the link between ALDH1 and radiation response in a wide variety of normal stem 
cell and CSC types.
Although it would appear that high ALDH1 activity offers cellular protection by 
conferring drug resistance, thereby enhancing the aggressiveness of CSCs. this may not
the case for malignant melanoma, a highly aggressive and drug-resistant cancer [138]. A 
study by Prasmickaite el al. showed that metastatic melanoma patient biopsies had a 
substantially large and distinguishable ALDH1+ subpopulation. However, both the 
ALDH1+ and ALDHL subpopulations displayed similar aggressive characteristics, in that 
they were both highly clonogenic in vitro, tumourigenic in vivo, and showed similar drug 
resistance to dacarbazine and the TRAIL-R2 agonist lexatumumab (anti-melanoma drug) 
[138], Perhaps malignant melanoma is an exception to the observation in other cancers 
that high ALDH1 contributes to high self-protection and enhanced cell aggressiveness, 
potentially due to the fact that there have been conflicting opinions regarding the 
existence of CSCs in malignant melanoma [138],
2.6.8 Studies on the Modification of Expression of ALDH in Cancer
There have been multiple studies using knockdown or overexpresssion methods in 
the past that modified the expression of ALDH1 and/or ALDH3 in various cancer model 
systems, including breast cancer, in relation to its contribution to drug resistance [74, 79, 
80. 83, 112], changes in global gene expression, and cellular proliferation and migration 
[111]. Since ALDH is an intracellular detoxification enzyme, it is not surprising that most 
of these studies focused on its effects on drug resistance. For example, it was observed 
that overexpression of ALDH 1 or ALDH3 enzymes resulted in an increased resistance to 
the cyclophosphamide drugs of interest, while knocking down ALDH1A1 and/or 
ALDH3A1 enzymes resulted in an increase in cyclophosphamide sensitivity in A549 lung 
cancer, MCF-7/0 breast adenocarcinoma, and K562 or 293T leukemic cell lines [74, 79.
80, 83, 112], It was also found that although knockdown of either ALDH1A1 and 
ALDH3A1 by siRNA conferred approximately the same sensitivity to the drug 4- 
hydroxycyclophosphamide (4-HC; the active metabolite of cyclophosphamide), there was 
an additive effect in drug sensitivity in the A549 lung cancer cell line when both isoforms 
were knocked dow'n in combination [79]. Interestingly, it would appear that the ALDH 
enzyme family may play additional functional roles in cancer cells besides their role in 
cellular detoxification. Using a microarray gene expression profile system, it was 
observed that knockdown of ALDH1A1 and ALDH3A1 affected a variety of genes in 
different biological and biochemical systems (either upregulated or downregulated). 
Additionally, it was found that knockdown of ALDH1A1/3A1 resulted in a decrease in 
cellular proliferation as well as migration in the A549 lung cancer cell line [111]. 
However, the functional role of ALDH enzymes in mediating breast cancer cell 
metastatic behaviour remains unknown.
2.7 Study Rationale
Despite advances in prevention, early detection and treatment of primary breast 
cancers, metastasis remains the main contributor to breast cancer mortality. In addition, 
although there is growing evidence supporting the role of CSCs in primary tumour 
growth, the functional and mechanistic contribution of these cells in metastatic behaviour 
remains poorly understood. We believe that the dearth of knowledge about CSCs and 
metastasis is due largely to technical challenges associated with the use of primary human 
cancer cells in preclinical models of metastasis: even in immunocompromised mice, it is 
very difficult to grow primary cells as xenograft tumours, much less as metastases.
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Therefore, a workable alternative model system must be developed and employed in 
order to address this need. Studies from our group [6, 7] and others [49-51, 72, 139-143] 
have shown that commonly used breast cell lines contain subpopulations of cells with 
phenotypic and functional stem-like properties. Thus, the purification of stem-like cells 
from cell lines can provide a valuable model system for investigating the role of these 
cells in metastasis. Another advantage to using cell lines is that all cells from a specific 
cell line should have similar karyotypic background, which is not always the case in 
primary tumour cells isolated from a patient. This will allow the generation of consistent 
and reproducible results from independent research groups in order to ensure the results 
are not an artifact.
Previous data from our lab has demonstrated that we can successfully isolate 
ALDHhlCD44+ stem-like cells from human breast cancer cell lines, and that these cells 
exhibit enhanced metastatic behaviour and therapy resistance compared to their 
ALDH10" CD44" counterparts [7], However, the functional role of ALDH enzymes in 
mediating breast cancer cell metastatic behaviour has not been investigated. Of the vast 
ALDH families and subfamilies, it has been shown that certain ALDH isoforms such as 
cytosolic ALDH1A1 and ALDH3A1 are particularly important for cancer cell behaviour. 
Several studies have demonstrated that high cytosolic ALDH1A1 and ALDH3A1 
expression and/or activity can offer cellular protection against cytotoxic drugs in 
preclinical model systems [44. 65, 79, 144], as well as affecting the malignant behaviour 
of cancer cells [111]. Additionally, in two independent studies analyzing 163 and 269 
primary prostate cancer patient samples (respectively), it was shown that patients with 
high ALDH1A1 expression had a higher Gleason score, higher pathologic stage, and
reduced overall survival [104, 105, 144], From the current literature in the field, as well 
as the fact that the Aldefluor® assay was developed to detect ALDH activity generated 
predominately by the ALDH1A1 isoform (personal communication, StemCell 
Technologies), we decided to focus on studying the ALDH1A1 isoform for this thesis.
The overall goal of the study was to begin to investigate whether ALDH1A1 functionally 
contributes to malignant behaviour, as opposed to simply being a marker of highly 
aggressive breast cancer cells.
35
36
2.8 Hypothesis, Objectives, and Aims
The hypothesis of this study is that overexpression of ALDH1A1 will enhance the 
metastatic behaviour of breast cancer cells in vitro.
The objective of this study is to investigate the functional role of ALDH1A1 in 
breast cancer cell behaviour.
The aims of this study are:
(1) To generate and validate stable cell lines overexpressing ALDH1A1.
(2) To assess the resulting functional effects of ALDH1A1 overexpression using in 
vitro assays of metastatic behaviour (growth, migration, adhesion, and colony­
forming ability).
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3.0 MATERIALS AND METHODS
3.1 Cells and Cell Culture
The non-metastatic MCF-7 human breast cancer cell line was obtained from 
American Type Culture Collection (ATCC; Manassas, VA), and was cultured in 
Dulbecco’s Modified Eagles Medium (DMEM; Invitrogen; Carlsbad, CA) + 10% fetal 
bovine serum (FBS; Sigma-Alrich; St. Louis, MO) in a 37°C humidified incubator with 
5% carbon dioxide (CO2). When the cells were approximately 70% confluent, cells were 
subcultured by washing with lx PBS (phosphate buffered saline) and trypsinizing with 
0.25% trypsin (Invitrogen) in citrate buffered saline for less than 5 minutes (or until the 
cells began to dissociate from the tissue culture flask), followed by quenching the trypsin 
reaction using DMEM + 10% FBS. The cell suspension was centrifuged at 1000 x g for 5 
minutes at room temperature (RT), followed by resuspension of the cell pellet in its media 
(DMEM + 10% FBS). MCF-7 cells were subcultured at a dilution of 1:10 in a T75 tissue 
culture flask every 3-4 days. Cells were used for experiments starting at the third passage 
after being thawed from frozen stocks, and were used for a maximum of 10 passages 
before fresh stocks were thawed.
3.2 Flow Cytometry
MCF-7 cells were tested for the expression of the prospective breast CSC 
phenotype CD44+CD24" and for activity of ALDFI using flow cytometry. One million 
MCF-7 cells were labelled with fluoresein isothiocyanate (FITC)-conjugated mouse anti­
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human CD44 (BD Biosciences Canada, Mississauga, ON), in combination with 
phycoerythrin (PE)-conjugated mouse anti-human CD24 (BD Biosciences Canada). To 
assess ALDH activity, lxlO6 MCF-7 cells were labelled with the Aldefluor® Assay Kit 
(StemCell Technologies, Vancouver, BC) as per the manufacturer’s protocol. Cells with 
high ALDH activity will uptake uncharged ALDH substrate (BODIPY- 
aminoacetaldehyde [BAAA]) by passive diffusion and then convert BAAA into 
negatively-charged BODIPY-aminoacetate (BAA ). BAA' is then retained inside cells, 
causing the subset of ALDHhl cells to become highly fluorescent. As a negative control,
1.5 mM of DEAB, a specific ALDH inhibitor, is used to quench the activity of ALDH11' 
cells (Figure 4). Cells were analyzed using a XCL flow cytometer (Beckman Coulter Inc., 
Mississauga, ON).
3.3 Plasmids and Cloning
3.3.1 Plasmids and Transformation
The plasmid construction and cloning strategy is outlined in Figure 6. The starting 
constructs were ALDH1 Al/pOTB7 (Open Biosystems/Thermo Scientific, Huntsville, 
AL), and a pcDNA3.1(+) mammalian expression vector (Invitrogen). The 
ALDH1 Al/pOTB7 construct contained a chloramphenicol resistance marker, while the 
pcDNA3.1 plasmid had the ampicillin resistance marker. Using 50 pi of NEB (New 
England Biolabs) 5-alpha competent Escherichia coli (E. coli) cells (New England 
Biolabs; Ipswich, MA), 0.5 pg of either the ALDH1 Al/pOTB7 or the pcDNA3.1 











MCS (multiple cloning site) 
of pcDNA3.1(+)
Figure 6. Cloning strategy and construction of the ALDHlAl/pcDNA3.1 
mammalian expression vector. The ALDH1A1 insert was digested out of 
ALDH1 Al/pOTB7 (A, top left) using EcoRI and Xhol (B), and inserted into the 
appropriate restriction enzyme sites of the multiple cloning site (MCS) of 
pcDNA3.1 (A, B). The resulting mammalian expression vector was
ALDHlAl/pcDNA3.1, where the ALDH1A1 transcript was under the control of the 
cytomegalovirus promoter (Pcmv)- The purified and expanded 
ALDH1 Al/pcDNA3.1 expression vector was used to transfect MCF-7 cells to 
stably overexpress ALDH1A1. Chlorar -  chloramphenicol resistance; ampr -  
ampicillin resistance; neor -  neomycin resistance.
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shock method at 42°C for approximately 1 min. The bacteria and plasmid DNA mixture 
was added to SOC (Super Optimal Culture) medium (Invitrogen) and incubated while 
shaking at 37°C for 1 hr to allow for the maximum transformation efficiency of E.coli 
cells. The appropriate dilution of the transformed cell mixture (transformed E. coli, 
Lennox broth (Bioshops; Burlington, ON) and 5 pg/ml chloramphenicol (Sigma) or 50 
pg/ml ampicilin (Invitrogen) for ALDH1 Al/pOTB7 orpcDNA3.1 respectively), was 
plated onto selective Luria Bertani (LB) agar (Sigma) plates containing the appropriate 
antibiotics using sterile aseptic technique, followed by incubation at 37°C overnight to 
allow for colony formation. For each replicate, 5 colonies were picked per plasmid 
transformations (ALDH1 Al/pOTB7 and pcDNA3.1) for expansion.
3.3.2 Expansion and Purification of Plasmids and Inserts
Picked E. coli colonies were incubated in the appropriate selective LB broth at 
37°C for 12-16 hrs while shaking to expand the transformed cells. Of the 5 clones chosen 
per transformation, plasmids from 3 clones were then isolated and purified using the 
QIAprep Spin Miniprep System (Qiagen, Valencia, CA), as per manufacturer’s protocols. 
Minipreps are designed to purify up to 20 pg of high-copy plasmid DNA from 1-5 ml E. 
coli cultures in LB medium. The transformed E.coli cultures were lysed in the presence of 
RNase A to remove any RNA present, and lysates were cleared by centrifugation. The 
resulting supernatant containing plasmid DNA was then applied to the QIAprep spin 
columns, which contain a silica gel membrane that binds up to 20 pg of DNA in the 
presence of a high concentration of chaotropic salt. The supernatant was then centrifuged
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through the columns, and washed several times until pure plasmid DNA was eluted in 
elution buffer (10 mM Tris-Cl, pH 8.5). Purified plasmid DNA was analyzed using the 
Nanodrop ND-1000 (Thermo Scientific; Waltham. MA) for spectrophotometry to ensure 
pure plasmid DNA as well as determine its concentration.
Once purified plasmid DNA was obtained, restriction enzyme digestion was 
performed to validate the plasmids isolated from each clone. Using 2 units of EcoRI 
(New England Biolabs), lx EcoRI buffer (NEBuffer 4; New England Biolabs) and 1 pg 
of pcDNA3.1, the plasmid was digested and linearized, followed by confirmation of 
plasmid size by agarose gel electrophoresis. In the presence of lx NEBuffer 4, 2.5 units 
of EcoRI and Xhol (New England Biolabs), and 100 pg/ml bovine serum albumin (BSA; 
New England Biolabs), 1 pg of ALDH1 Al/pOTB7 was double-digested so that the 
ALDH1A1 insert was separated from the linearized pOTB7 via agarose gel 
electrophoresis. Of the 3 clones from each plasmid, one clone was chosen for expansion 
via QIAprep midiprep system based on its correct plasmid (pcDNA3.1) and insert 
(ALDH1 Al) size (Figure 7) and sequencing results. The midiprep system is essentially 
the same as the miniprep system, except the midiprep system is on a larger scale that 
results in up to 100 pg of purified plasmid DNA. Five micrograms of the purified and 
linearized pcDNA3.1 plasmid and ALDH1 Al insert was extracted post-agarose gel 
electrophoresis using the QIAEXII Gel Extraction kit (Qiagen), as per manufacturer’s 
protocol. The resulting plasmid/QIAEXII mixture was then washed, followed by eluting 





























Figure 7. Confirmation of the ALDH1A1 cDNA insertion into the pcDNA3.1 
expression vector. After ligation of the ALDH1A1 insert into the pcDNA3.1 
vector, purified minipreps of ALDH1 Al/pcDNA3.1 underwent double restriction 
enzyme digestion using EcoRI and Xhol, followed by agarose gel electrophoresis 
to confirm the plasmid and insert sizes. Undigested empty vector (pcDNA3.1) and 
undigested expression vector (ALDH1 Al/pcDNA3.1) were also examined by 
agarose gel electrophoresis. The arrow indicate the clone chosen for midipreps to 
obtain the plasmid stocks, where its sequence was confirmed, and was later used 
for transfection of MCF-7 cells. RT = ligation performed at room temperature for 
1 hr, and 14 °C = ligation performed at 14 °C for 16 hrs.
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diethylpyrocarbonate (DEPC)-treated water at 50°C for 5 minutes to remove and purify 
the plasmid DNA from the silica beads. The final purified plasmid DNA product was then 
measured using the Nanodrop for spectrophotometry.
3.3.3 Plasmid Ligation, Insertion and Confirmation
The purified ALDH1A1 insert was ligated into the purified linearized pcDNA3.1 
plasmid at a 3:1 molar ratio using T4 DNA ligase (Invitrogen), as per the manufacturer's 
protocol. Ligation was performed at either RT for 1 hr or at 14°C for 16 hr, followed by 
transformation of the NEB 5-alpha competent E. coli cells with ALDH1 Al/pcDNA3.1 as 
described above. Miniprep and midipreps were performed to expand and purify the 
ALDH1 Al/pcDNA3.1 plasmids, followed by gel extraction to confirm the plasmid and 
insert size as described previously. All plasmids and inserts (ALDH1 Al/pcDNA3.1) from 
the beginning of the cloning protocol until the end were sent for sequencing at the 
Robarts Research Institute after each step as another method to further validate the 
plasmids and inserts.
3.4 Stable Transfections
3.4.1 Antibiotic Kill Curve Assay
The ALDH1 Al/pcDNA3.1 plasmid contains a neomycin resistance marker, 
therefore antibiotic dose killing curve experiments were performed to determine the 
concentration of the antibiotic geneticin (G418; Invitrogen) needed to kill the non-
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transfected MCF-7 cell lines, to ensure there were no resistant parental cells. MCF-7 cells 
at approximately 75% coniluency were treated with various concentrations of G418 in 
normal growth media and cultured at 37°C, 5% CCK and the percentage of confluent cells 
were observed every day. The resulting concentration identified to kill 100% of the 
parental MCF-7 cells was 800 pg/ml of G418 (data not shown), which was used to select 
and screen for MCF-7 cells transfected with ALDH1 Al/ pcDNAS.l or the pcDNA3.1 
empty vector as described below.
3.4.2 Stable Transfection
The stable transfection strategy is outlined in Figure 8. Parental MCF-7 cells were 
transfected with 2 pg of ALDH1 Al/pcDNA3.1, or pcDNA3.1 (empty vector control) 
using 5 pL of Lipofectamine 2000 (Invitrogen) for 4-6 hours in 100 mm dishes, and 
passaged at a dilution of 1:3 into new 100 mm dishes as per the manufacturer's 
guidelines. Cells were maintained in 800 pg/ml geneticin (G418), and the selective media 
(DMEM + 10% FBS + 800 pg/ml G418) was changed every 3-4 days until distinctive 
colonies formed on the 100 mm dishes. Colonies formed approximately 18 days after 
transfection, at which point each colony was harvested and added to 1 ml of selective 
media per well of a 24-well plate. In total, 57 colonies were picked (40 for MCF- 
7/ALDFI1 Al, 17 for MCF-7/pcDNA3.1), and were maintained in a 24-well plate format 
until each clone became confluent. Once the clones became confluent, they were 
transferred to a T25 flask, allowed to grow to coniluency, transferred to a T75 flask 
before being expanded for screening and selection, or for freezing down for storage and
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Figure 8. Stable transfection strategy. Parental MCF-7 cells were transfected with 
2 jug of ALDHlAl/pcDNA3.1, or pcDNA3.1 (empty vector control) using 5 pL of 
Lipofectamine 2000® for 4-6 hours in 100 mm dishes (D a y  1), and passaged at a 
dilution of 1:3 into new 100 mm dishes (D a y  2) as per the manufacturer’s 
guidelines. The cells were maintained in selective media (DMEM + 10% FBS + 800 
pg/ml G418), which was changed every 3-4 days until distinctive colonies formed 
on the 100 mm dishes ( - D a y  18). Colonies formed approximately 18 days after 
transfection, at which point each colony was harvested and added to 1 ml of 
selective media per well of a 24-well plate. In total, 57 colonies were picked (40 for 
MCF-7/ALDH1 Al, 17 for MCF-7/pcDNA3.1), and were maintained in a 24-well 
plate format until each clone became confluent. Once the clones became confluent, 
they were transferred to a T25 flask { -D a y  25), allowed grow to confluency, and 
transferred to a T75 flask (-Day 30) before being expanded for screening and 
selection, frozen down for storage, or harvested for further studies.
further studies. Once the clones had been screened and selected, they were combined 
together to generate a pooled population of MCF-7/pcDNA3.1 (empty vector control) or 
MCF-7/ALDH1A1 cells in order to control for clonal heterogeneity.
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3.5 Enrichment of ALDHhl Population via Fluorescence Activated Cell Sorting
(FACS)
In order to enrich for the ALDHhl population, stably transfected MCF- 
7/ALDH1A1 cells was subjected to FACS on the basis of the ALDFI activity. Cells were 
labelled with the Aldefluor® Assay Kit as described above, in conjunction with the cell 
viability stain 7 aminoactinomycin D (7-AAD; BD Pharmingen, Mississauga, ON). The 
ALDH sorting criteria was set as previously described [6, 7], Briefly, the top 20% of the 
population was considered to be ALDFlhl, while the bottom 20% was considered to be 
ALDHlow. Cell viability was assessed by 7-AAD staining during cell sorting. Cells were 
sorted at the London Regional Flow Cytometry Facility (Robarts Research Institute) 
using a FACSAria instrument, and analyzed using FACSDiva version 6.1.2 (BD 
Biosciences). After cell sorting, cells were immediately cultured in the G418 selective 
media with 5% penicillin/streptomycin (Invitrogen).
3.6 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
3.6.1 Primer Design
The primers for the target gene (ALDH1 Al) were designed using Primer3 
(version 0.4.0). Three different sets of primers (where each set included a sense and an
anti-sense primer) were selected from Primer3 on the basis that they were near the 5’. 
middle, and 3' end of the ALDH1A1 gene, with PCR products having an expected size of 
250 base pairs (bp) or less. These primers were purchased from Integrated DNA 
Technologies (IDT; Coralville, IA). Gradient PCR was performed on cDNA from MDA- 
MB-468 cells as a positive control to determine the annealing temperature that would 
give the expected amplicon sizes when confirmed via gel electrophoresis of the PCR 
product. Glyceraldhyde 3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene since its expression did not change under various conditions, and was 
amplified using primers already in use in the lab (Sigma). Primer sequences and 
annealing temperatures are presented in Table 2.
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3.6.2 RNA Isolation
Using the TRIzol® reagent (Invitrogen), RNA was isolated from cells at -70% 
confiuency as per manufacturer's protocol. Media w'as removed and cells were washed 
twice with cold PBS before adding the TRIzol® reagent to the cells. TRIzol® was left on 
the cells for approximately 5 min at RT to allow the cells to lyse, followed by scraping 
the cells off the surface using a cell scraper to further lyse the cells. The cell homogenate 
was then transferred to an RNase-free microtube, followed by addition of chloroform 
(BioShop) and centrifugation to separate the phases. The top aqueous phase containing 
RNA was transferred to a new microfuge tube, followed by the addition of isopropanol to 
precipitate out the RNA. The RNA-isopropanol solution was centrifuged to obtain a RNA
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Table 2 . Primer sequences of the target genes to be tested for RT-PCR.
Gene Symbol 
(Human)





ALDHIAl-f/r cgttggttatgctcatttggaa tgatcaacttgccaacctctgt 249 55.2
GAPDH-f/r catgttcgtcatgggtgtgaacca atggcatggactgtggtcatgagt 152 60
Forward and reverse primers for the specific genes have a product length of the corresponding base pairs. 
Tm -  annealing temperature at which the primers bind optimally to its target sequence 
ALDH1AI -  Aldehyde dehydrogenase-1A 1
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pellet, which was then washed with ice cold 75% ethanol, and resuspended in nuclease- 
free DEPC-treated H2O (Invitrogen). Spectrophotometry was performed using the 
Nanodrop ND-1000 to analyze total RNA for concentration and purity, followed by 
resolving 2 pg of each sample on 1% agarose gel electrophoresis at 100V to determine 
RNA integrity.
3.6.3 cDNA Synthesis, RT-PCR and Agarose Gel Electrophoresis
cDNA was synthesized from 2 pg of total RNA using Superscript III® Reverse 
Transcriptase, as per the manufacturer's protocol (Invitrogen). Two microgram of total 
RNA was primed at 65°C for 5 min using oligo(dT)|2-i8, a dNTP mix (containing ATP, 
CTP, GTP, TTP), and DEPC-treated H20 (nuclease-free). A reverse transcription reaction 
using dithiothreitol (DTT), RNase Out, Superscript III® Reverse Transcriptase, and First 
Strand Reaction buffer (Invitrogen) was performed at 55°C for 1 hr, after which the 
reaction was stopped at 70°C for 15 min. The resulting cDNA was treated with RNase H 
(ribonucléase H; Invitrogen) at 37°C for 20 min to eliminate any residual RNA in the 
cDNA mixture. Total cDNA was diluted in nuclease-free DEPC-treated water.
Twenty-live nanograms of input RNA (cDNA) with 0.25 pM of each of the 
forward and reverse ALDH1A1 and GAPDH primers were added to lx Taq Buffer, 1.5 
mM MgCl2, 0.2 mM dNTP and 0.5 units of Taq Polymerase (Invitrogen). Instead of 
cDNA, water was also added to the mixture as a no template control (NTC). The cDNA 
or NTC reaction mixture was subjected to PCR using a thennocycler (Eppendorf Master 
Cycler Gradient; Hamburg, Germany). The thermocycling conditions were as follows: 
initial dénaturation at 95 °C for 2 min; 35 cycles of dénaturation at 95 °C for 30 seconds.
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annealing for 30 seconds at 55.2 °C or 60 °C for ALDH1A1 or GAPDH, respectively, 
extension at 72 °C for 45 seconds; with a final elongation at 72°C for 10 minutes before 
being cooled at 4°C.
PCR products were resolved at 100 V in a 2% agarose gel in lx TBE [tris-borate- 
ethylenediamine tetra-acetic acid (EDTA)] buffer with ethidium bromide (BioRad) to 
stain the nucleic acids present, followed by imaging the gel under ultraviolet (UV) light 
using a Gel Doc apparatus and Quantity One 4.6.1 software (BioRad). Densitometry 
analysis was performed using ImageQuant5.1 software (Molecular Dynamics, Sunnyvale, 
CA), where the density of the ALDH1A1 PCR product was normalized to GAPDEI PCR 
product.
3.7 Western Blotting
3.7.1 Protein Lysate Isolation
Cells were grown in 100 mm tissue culture plates to approximately 75% 
confluency before the cells were trypsinized and harvested for protein lysate collection. 
Harvested cells were washed twice with cold lx PBS before resuspension in lysis buffer 
with a cocktail of protease inhibitors (1 mM phenylmethanesulfonyl fluoride (PMSF), 0.1 
mM benzamidine, 5 pg/ml leupeptin, pepstatin A, and aprotinin; all purchased from 
BioShop). The cells were pipetted up and down in the lysis buffer and incubated at 4°C 
for 1 hr on a nutator to facilitate cell lysis. Lysates were cleared by centrifugation at
13,000 x g for 20 min at 4°C. where the protein lysate supernatant from each sample was
then measured using the BioRad’s “Dc” Protein Assay to determine the protein 
concentration, as per manufacturer's protocol.
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3.7.2 Gel Electophoresis and Immunoblotting
Twenty-five microgram of protein was combined with electrophoresis sample 
buffer [0.5M Tris HC1 (pH 6 .8 ), 10% SDS (sodium dodecyl sulphate), 0.5% bromophenol 
blue, 100% glycerol (Wisent Bioproducts, St. Bruno, Quebec), and 2-mercaptoethanol 
(Bioshop)] , boiled for 5 min to denature, and snap cooled on ice. Kaleidoscope Precision 
Plus Protein Standards (BioRad; 10-250 kDa) and protein samples were loaded into 
separate wells of a 12% SDS-polyacrylamide resolving gel with a 5% SDS- 
polyacrylamide stacking gel. Gel electrophoresis separated the proteins at 125V in lx 
Tris-glycine running buffer (pH 8.3), followed by transfer onto polyvinylidene fluoride 
(PVDF) membranes (Bio-Rad) overnight at 30 V in transfer buffer (pH 8.3) at 4°C. 
Membranes were blocked with a 5% milk solution (dry skim milk powder in Tris- 
buffered saline + 0.1% Tween-20 [TBS-T]) for 1 hr at RT to block non-specific binding. 
The PVDF membranes were incubated with rabbit polyclonal anti-human ALDH1A1 
(1:1000; Abeam, Cambridge, UK) or rabbit anti-actin (loading control, 1:5000, Sigma) 
primary antibodies in 5% milk/TBS-T for 1 hr at RT. The blots were washed with lx 
TBS-T to remove unbound antibodies, followed by incubation with goat anti-rabbit IgG 
conjugated to horse-radish peroxidase (HRP; 1:3000; Abeam) in 5% milk/TBS-T for 1 hr 
at RT. Blots were washed with lx TBS-T before adding enhanced chemiluminescence 
(ECL) Plus Western Blot Detection System (GE Health Care, UK) to detect protein 
signals as per manufacturer's protocol. The blots were scanned using the STORM 860 
Molecular Imager (phosphoimager/fluoroimager; GE Health Care Life Sciences).
Densitometry of the protein bands were quantified using ImageQuant 5.1 software 
(Molecular Dynamics), where the protein densities of ALDH1A1 were normalized to 
actin.
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3.8 In  vitro  Assays of Metastatic Behaviour
3.8.1 Proliferation Assay
Parental MCF-7 and transfected (MCF-7/pcDNA3.1 and MCF-7/ALDH1 Al) cells 
were plated at 50,000 cells in 60 mm dishes in triplicate. Every 48h for two weeks, cells 
were counted using trypan blue exclusion and light microscopy. Cell counts from each 
day were normalized to the cell count from day one for each cell line to determine the 
fold change of cellular proliferation. From the proliferation assay, one can also determine 
the doubling time of the cells by using the formula as described previously [145]:
To = K/t; where K = [Iog(N,) -  log(Nn) x 3.32]; Nt = number of cells after a 
certain time (length of the experiment); N0 = initial number of cells; and t = time of 
experiment (hours).
3.8.2 Scratch Wound Migration Assay
Transfected MCF-7/pcDNA3.1 and MCF-7/ALDH1 Al cells were plated onto 24- 
well glass bottom dishes in triplicate and allowed to grow to confluency in normal growth 
medium. A wound was introduced to the cells once they reached approximately 90% 
confluency by scratching the surface of the cells using a sterile P10 pipette tip. Wells
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were washed with PBS to remove debris before adding regular media with or without 0.5 
|ug/ml mitomycin C (Sigma) at time 0. Mitomycin C stops proliferation by crosslinking 
DNA [ 146j and thus in the presence of mitomycin C in can be concluded that any 
observed wound closure will be due to migration, rather than due to proliferation. Images 
of the wounds were taken at time Oh, 8 h, 12h, 24h and 48h with and Olympus CK 
X41 microscope with the Q Colours Olympus camera, followed by image analysis using 
Image J (National Institute of Health, (NIH), Bethesda, MA).
3.8.3 Adhesion Assay
MCF-7/pcDNA3.1 and MCF-7/ALDH1A1 cells (lx l04 cells per well) were plated 
onto 96-well plates coated with vitronectin (5 pg/ml; Sigma) or lx PBS (negative control) 
that were blocked with serum-free media containing 0.1% BSA. Vitronectin was chosen 
as the matrix for the transfected MCF-7 cells to adhere to because MCF-7 cells are known 
to express the vitronectin receptor av|35 integrin [147, 148], Cells were allowed to adhere 
for 5h at 37°C, 5% CO2, fixed with 10% formalin (w/v) in neutral buffered PBS (Fisher 
Scientific Chemicals, Toronto, ON), permeabilized with 0.1% Triton X-100 (Acros, New 
Jersey) in PBS, blocked in 5% BSA (BioShop) in PBS, stained with ProLong® Gold anti­
fade mounting reagent with 4 \  6-diamidino-2-phenylindole (DAPI; Invitrogen) and dried 
overnight before counting the adhered cells under an inverted fluorescent microscope 
(Olympus 1X70). Cells in 5 fields of view (FOV) at 20x magnification per plate were 
counted and averaged.
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3.8.4 Colony Formation Assay
Parental MCF-7 and transfected (MCF-7/pcDNA3.1 and MCF-7/ALDH1A1) cells 
were plated at 100  cells per well in 6 -well dishes in triplicate, and were incubated 
undisturbed for two weeks at 37 °C, 5% CO2. These experimental conditions were 
optimized so that the resulting colonies would not grow into each other at endpoint. 
Resulting colonies were fixed with 1% gluteraldehyde, and stained with hematoxylin and 
1% ammonium hydroxide (NFI4OH), a mordant to hematoxylin. Colonies were allowed to 
dry overnight and were imaged under light microscopy using an Olympus CK 
X41 microscope with the Q Colours Olympus camera. Images were analyzed for colony 
size using Image J software (N1H) by measuring the largest diameter of each colony. 
Colony numbers were counted visually under the light microscope.
3.8.5 Cell Cycle Analysis using DRAQ5® with the Aldefluor® Assay
DRAQ5® (BioStatus Ltd., Leicestershire, UK) is a live cell DNA stain that emits 
in the far red fluorescent region. It was chosen for the cell cycle analysis because 
DRAQ5® does not require the cells to be fixed and permeabilized, and thus can be used 
in combination with the Aldefluor® Assay (green fluorescence) in flow cytometry assays 
that give a single-cell readout. Transfected cells (MCF-7/pcDNA3.1 or MCF- 
7/ALDFU A1) were either cultured in normal growth medium as a control, or serum 
starved for 48h. Cells were then treated with serum-containing media for 24h, after which 
the cells were harvested and analyzed by flow cytometry. One million MCF-7/pcDNA3.1 
or MCF-7/ALDH1A1 cells were labelled with the Aldefluor® reagent as described
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previously, followed by staining 5x10s cells with lOpM DRAQ5® at 37°C for 5 minutes. 
Samples were analyzed on Navios™ flow cytometer (Beckman Coulter Inc.). The gating 
strategy for the Aldefluor® Assay was as described previously, where the top 20% of the 
population gated based on the DEAB negative control was considered “ALDHhl”. 
However, for the DRAQ5®/Aldefluor® Assay, an additional gate was added, called 
“ALDHhlghLSt", which was gated as the top 20% of the "‘ALDHhl'’ gate. The remaining 
ungated cells were considered ‘‘ALDH"'\ Each of these gates was then analyzed for cell 
cycle status from the fluorescence of the DRAQ5® labelled nucleus. Cells that fall under 
the first peak, valley and second peak were considered to be cycling in the Go/G], S, and 
G2/M phase, respectively.
3.9 Statistical Analysis
All experiments were performed with internal triplicates, and were repeated on 3 
separate occasions (n=3). Statistical analysis was performed using GraphPad Prism 4.0 
software (San Diego, CA). Data are reported as mean ± standard error of the mean 
(S.E.M.). A one-way ANOVA (analysis of variance) was used to determine the 
significant differences among multiple means, whereas a two-way ANOVA was used to 
determine the significant differences among multiple means with multiple independent 
factors. The level of significance for all statistical analyses was deemed to be p < 0.05. 
The Dunnett's multiple comparison post-hoc test was used if significance was seen in 




4.1 Aim 1: Generation and validation of stable cell lines overexpressing
ALDH1A1
4.1.1 Parental MCF-7 cells have minimal ALDHhl and CD44+CD24‘ populations
In order to confirm that the non-metastatic MCF-7 cells have an ALDHlowCD44low 
phenotype, MCF-7 cells were first tested for the expression of the prospective breast CSC 
phenotype CD44+CD24~ and for activity of ALDFF We observed that the MCF-7 cell line 
has low basal levels of CD44 expression and low ALDH activity, with only 0.57% ± 
0.36% of the population showing increased ALDH activity relative to control (Figure 
9A). As a positive control for the Aldefiuor® Assay, the weakly metastatic cell line 
MDA-MB-468 (known to contain a subpopulation of ALDHhl cells [6 , 7J), was also 
assessed for ALDH activity, and demonstrated high ALDH activity (68.3% ± 8.3% of 
population) (Figure 9B). For both the MDA-MB-468 and MCF-7 cell lines, 1.5 mM of 
the specific ALDH inhibitor DEAB was used to quench the ALDH activity, and the gate 
was determined based on the DEAB negative control (Figure 9AB, tup panels). In 
addition, 0.00% of the population was observed to express the prospective breast CSC 
phenotype CD44+CD24' {Figure 9C). The CD44/CD24 expression and ALDH activity 
results for both MCF-7 and MDA-MB-468 cell lines are in concordance with previously 
published data [7], Taken together, this indicates that MCF-7 cells are a good candidate 
human breast cancer cell line which to overexpress ALDH1A1 and investigate its
functional contributions in breast cancer cell behaviour.
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Figure 9. Parental MCF-7 cells have minimal ALDHhl and CD44+CD24" 
populations. Cells were analyzed for ALDH activity (A, B) and expression of 
the prospective breast CSC phenotype CD44+CD24~ (Q  by flow cytometry. (A) 
Representative dot plots of (A) non-metastatic MCF-7 cells or (B) weakly 
metastatic MDA-MB-468 cells (positive control) labelled with ALDH substrate 
(Aldefluor®) (bottom panels). Treatment of cells with the specific ALDH 
inhibitor DEAB was used as a negative control {top panels). (C) Representative 
histograms ot CD44 expression {top panel; black profiles) relative to a negative 
control where MCF-7 cells were not labelled with any antibodies {top panel; 
white profiles). Representative dot plots of CD24-PE versus CD44-F1TC 
expression {bottom panels). All experiments were performed in triplicate (n=3).
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4.1.2 Generation of the ALDH1 Al/pcDNA3.1 expression vector and stable 
transfection of MCF-7 human breast cancer cells
The ALDHlAl/pcDNA3.1 expression vector was generated as described in the 
Materials and Methods and in Figures 6 and 7. Non-metastatic MCF-7 human breast 
cancer cells were transfected with the ALDH1 Al/pcDNA3.1 expression vector or an 
empty vector control (pcDNA3.1) as described in the Materials and Methods and Figure 
8. Two methods were used to validate the MCF-7/pcDNA3.1 and MCF-7/ALDH1A1 
clones and pooled populations: RT-PCR and immunoblotting.
4.1.3 Screening of MCF-7/ALDH1A1 and MCF-7/pcDNA3.1 clones and pooled
populations using RT-PCR
Total cellular RNA was collected from individual transfectant cell lines so that 
ATDF11A1 mRNA expression could be screened by semi-quantitative RT-PCR. Fluman 
ALDH1A1 primers were designed as described previously and GAPDH was used as a 
housekeeping gene control (Table 2). Although RT-PCR screening was performed on all 
individual clones generated, Figure 10 shows analysis of a representative selection of cell 
lines, including MDA-MB-468 (positive control), parental MCF-7 (negative control), 
MCF-7/pcDNA3.1 pooled population (empty vector control), MCF-7/ALDH1A1 clones 
29, 33, 35, 38 (the only positive clones on initial screening) and MCF-7/ATDFI1A1 
pooled populations (initial pool of clones 29 + 33 + 35 + 38; and the FACS sorted pooled 
population). It was observed that while all MCF-7/ALDF11A1 clonal and pooled 
populations demonstrated an increase in ALDH1A1 expression, due to the semi-
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Figure 10. Analysis of ALDH1A1 mRNA expression using RT-PCR. A pooled 
population (pooled MCF-7/ALDH1A1) was generated from four positive 
(ALDH 1A1 -29, -33, -35, -38) clones. The pooled population was further enriched 
for ALDHhl cells by FACS (sorted MCF-7/ALDH1A1). Total RNA from clones 
generated from the stable transfections were collected and analyzed by RT-PCR. 
ALDH1A1 mRNA was normalized to GAPDH, where fold change of expression 
was determined by comparing the experimental groups to the empty vector 
control cells (MCF-7/pcDNA3.1). The MDA-MB-468 cell line was used as a 
positive control. Densitometry quantification of the ALDH1A1 mRNA expression 
(n=3) was performed by lmageQuant5.1 and presented as mean ± S.E. * = 
significantly different than MCF-7/pcDNA3.1 empty vector control (p < 0.05).
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quantitiative nature of RT-PCR only the sorted MCF-7/ALDH1A1 pooled population 
demonstrated statistically significant overexpression of the ALDH1A1 transcript when 
compared to the empty vector control (Figure 10) (p < 0.05; one-way ANOVA with 
Dunnett's multiple comparison’s test analysis, n=3).
4.1.4 Screening of MCF-7/ALDH1A1 and MCF-7/pcDNA3.1 clones and pooled
populations using immunoblotting
Protein expression of ALDH1A1 was assessed using immunoblotting. Although 
immunoblotting was performed on all individual clones generated, Figure 11 shows 
analysis of a representative selection of cell lines, including MDA-MB-468 (positive 
control), parental MCF-7 (negative control), MCF-7/pcDNA3.1 pooled population 
(empty vector control), MCF-7/ALDH1A1 clones 29, 33, 35, 38 (the only positive clones 
on initial screening) and MCF-7/ALDF11A1 pooled populations (initial pool of clones 29 
+ 33 + 35 + 38; and the FACS sorted pooled population). Similar to the RT-PCR results, 
immunoblotting confirmed that there were four ALDF11A1-positive clones (29, 33, 35, 
and 38). MDA-MB-468, ALDH1A1-29, ALDH1A1-33, and the sorted MCF- 
7/ALDF11A1 pooled population demonstrated statistically significant increase in 
ALDH1A1 protein expression relative to the MCF-7/pcDNA3.1 empty vector control 
(Figure 11) (p < 0.05; one-way ANOVA with Dunnett's multiple comparison's test 
analysis, n=3). Interestingly, the protein and mRNA expression profile of the MDA-MB- 
468 and the sorted MCF-7/ALDH1A1 cell line are in discordance with each other. For 
example: the mRNA expression of MDA-MB-468 and sorted MCF-7/ALDH1A1 is 
approximately 50-fold and 300-fold increased, respectively, when compared to the
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Figure 11. Analysis of ALDH1A1 protein expression. Protein lysates were 
collected from MDA-MB-468, MCF-7, MCF-7/pcDNA3.1, MCF-7/ALDH1A1 
clones, pooled and sorted populations, followed by western blotting (n=3). Blots 
were probed with anti-ALDHIAl and anti-actin antibodies, where actin was used as 
a loading control. ALDH1A1 protein expression was normalized to actin, where fold 
change of expression was determined by comparing the experimental groups to the 
MCF-7/pcDNA3.1 cells. Densitometry analysis was completed using ImageQuant5.1 
and presented as mean ± S.E. (n=3). * = significantly different than MCF- 
7/pcDNA3.1 empty vector control, (p < 0.05).
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mRNA expression MCF-7/pcDNA3.1. On the other hand, the protein expression of 
MDA-MB-468 and sorted MCF-7/ALDH1A1 is approximately 35-fold and 5-fold 
increased, respectively, relative to the protein expression MCF-7/pcDNA3.1.
Since it was observed that both ALDF11A1 mRNA and protein expression of the 
sorted MCF-7/ALDH1A1 pooled population was statistically significantly higher than the
empty vector control MCF-7/pcDNA3.1 (Figure 10. 77), this cell line (referred to from 
now on as simply MCF-7/ALDH1 Al) was used for the remainder of the study to assess 
the effect of ALDH1 Al overexpression on breast cancer cell metastatic behaviour. 
ALDH1A1 protein expression of MCF-7/ALDH1 Al and MCF-7/pcDNA3.1 stably 
transfected cell lines w as monitored throughout the course of the different functional 
experiments in order to confirm maintenance of stable overexpression of ALDH1 Al 
(data not shown).
4.2 Aim 2: Assessment of the functional effects of ALDH1A1 overexpression 
using in v itro  assays of metastatic behaviour
The differential cell behaviour of human breast cancer cells overexpressing 
ALDH1A1 was assessed using standard in vitro assays for cell proliferation, migration, 
adhesion and colony formation, as previously described in our lab [7],
4.2.1 MCF-7/ALDH1A1 cells do not show enhanced proliferation
We first wanted to assess whether overexpression of ALDH1 Al would enhance breast 
cancer cell proliferation, as this was found to be the case in lung cancer cells [1 1 1] as well
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as ALDHh'CD44+ breast cancer cells [7], Furthermore, inhibition of ALDH using DEAB 
or ATRA resulted in reduced proliferation in ALDHhlCD44+ cells derived from the 
MDA-MB-468 cell line [6 ]. However, assessment of proliferation in regular culture (n=3) 
demonstrated no statistical significance in cell number or doubling time between MCF- 
7/ALDH1A1 and MCF-7/pcDNA3.1 cell lines (Figure 12) (p > 0.05).
4.2.2 MCF-7/ALDH1A1 cells do not show enhanced migratory behaviour when 
using the scratch w ound assay
Differences in migration were assessed using a scratch wound assay, in the 
presence or absence of mitomycin C (an anti-proliferative agent [146]) in order to 
determine if ALDH1A1 would enhance migration, similar to what Moreb el al. found in 
lung cancer cells [111], as well as in our ALDHh'CD44+ breast cancer cells [7]. Again, no 
significant differences in wound closure/migration were observed between MCF- 
7/ALDH1 Al and MCF-7/pcDNA3.1 cell lines, regardless of the presence of absence of 
mitomycin C (Figure 13) (p > 0.05).
4.2.3 MCF-7/ALDH1 Al cells do not show enhanced adhesion to vitronectin
We also assessed the effect of ALDH1 Al overexpression on breast cancer cell 
adhesion as we previously observed that ALDHh'CD444 cells showed enhanced adhesion 
when compared to ALDHlo"CD44' cells [7]. Vitronectin was chosen as the extracellular 





Figure 12. 1MCF-7/ALDH1A1 cells do not show enhanced proliferation.
Parental MCF-7 cells and the transfected MCF-7 cell lines were plated for a 
standard proliferation assay in regular culture conditions. 50,000 cells were 
plated in triplicate in 60 mm dishes, incubated at 37 °C, 5% CO2, and cells 
were counted every 48 hrs using trypan blue exclusion (n=3). (A) Cell 
proliferation over time shown as fold-change relative to Day 1. (B ) Doubling 
time. Data is presented as mean ± S.E. No significant differences between cell 
lines were observed (p > 0.05).
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Figure 13. MCF-7/ALDH1A1 cells do not show enhanced migration. A
scratch wound assay was used as an indirect measurement of migration. MCF- 
7/ALDH1A1 and MCF-7/pcDNA3.1 cells were plated onto triplicate wells in 24- 
well glass bottom dishes and allowed to grow to confluency in normal selective 
growth medium (n=3). A wound was introduced to the monolayer of cells by 
scratching the surface of the cells using a sterile P10 pipette tip. Cells were 
washed with PBS to remove debris before adding either regular selective media 
[(-) mitomycin C] or with 0.5 jig/ml mitomycin C [(+) mitomycin C] at time Oh. 
Images of the wounds were taken at time Oh, 8 h, 12h, 24h and 48h with Olympus 
CK X41 microscope with the Q Colours Olympus camera, followed by a scratch 
wound analysis using Image J. The wounds at the different time points were 
normalized to Oh, and the results from the 48h time point are shown. Data is 
presented as mean ± S.E. No significant differences between cell lines were 
observed {p > 0.05).
receptors cxvp5 integrin [147, 148]. No statistical significant differences in adhesion 
between MCF-7/ALDH1A1 and MCF-7/pcDNA3.1 cell lines to either the PBS control or 
to vitronectin was observed (Figure 14) (p > 0.05).
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4.2.4 MCF-7/ALDH1A1 cells do not show enhanced colony forming ability
Finally, we wanted to test the influence of ALDH1A1 overexpression on the 
colony-forming ability of MCF-7 cells, as we have found previously that ALDHhl/CD44+ 
breast cancer cells showed enhanced colony formation abilities when compared to the low 
expressing counterparts [7], However, no significant differences in the number of 
colonies formed or the average colony size were observed between MCF-7/ALDH1A1 
and MCF-7/pcDNA3.1 cell lines (Figure 15) (p > 0.05).
4.2.5 MCF-7/ALDH1A1 cells contain only a small proportion of cells with high
ALDH activity
Despite the fact that MCF-7/ALDH1A1 cells demonstrate stable overexpression of 
ALDH1A1 at the transcript and protein level, the results of the functional assays for 
proliferation, migration, adhesion and colony formation did not support our hypothesis 
that overexpression of ALDH1A1 w ould enhance the metastatic behaviour of breast 
cancer cells in vitro. Since ALDH1A1 is an enzyme, ŵe decided to examine ALDH 
activity in the transfected cells and clones by using the Aldefluor® Assay as described in 
the Materials and Methods section. MDA-MB-468 and the sorted MCF-7/ALDH1A1 
pooled population were observed to have a statistically significantly higher proportion of 
ALDH11' cells relative to the MCF-7/pcDNA3.1 empty vector control (one way ANOVA
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Figure 14. MCF-7/ALDH1 Al cells do not show enhanced adhesion. A 96 well 
plate was coated either with PBS (negative control) or 5 pg/ml vitronectin before 
being blocked with serum free media containing 0.1% BSA. For both cell lines, 
lxlO4 cells/well were plated into triplicate wells and incubated at 37°C for 5h to 
allow cell adhesion, followed by fixing and staining (n=3). Cells that adhered to 
the PBS control or the vitronectin matrix were counted using 5 field of view 
(FOV) at a 20x magnification. Data is presented as mean ± S.E. No significant 
differences between cell lines were observed {p > 0.05).
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Figure 15. MCF-7/ALDH1A1 cells do not show enhanced colony 
forming ability. For the colony formation assay, 100 cells/well from 
parental MCF-7 or the transfected MCF-7 cell lines were plated in 
triplicate in 6  well dishes (n=3) and incubated at 37 °C, 5% C02 for 2 
weeks before the colonies were fixed, stained, and analyzed using Image 
J. (A) Mean number of colonies formed. (B ) Mean colony size. Data is 
presented as mean ± S.E. No significant differences between cell lines 
were observed (p > 0.05).
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with Dunnett’s multiple comparison test). However, although 68.3 ± 8.3% of the MDA- 
MB-468 population demonstrated high ALDH activity, only 11.25 ± 1.99% of the sorted 
MCF-7/ALDH1A1 pooled population were ALDHhl (Figure 16) (p < 0.05). Interestingly, 
enzyme activity and protein expression are in concordance with each other, such that the 
sorted MCF-7/ALDH1A1 ALDH activity and ALDH1A1 protein expression was 6 -fold 
less that of MDA-MB-468. Using serial FACS sorting to enrich the population for 
ALDHhl cells, we were unsuccessful at obtaining a cell population with a stable ALDH111 
population greater than - 1 2% (data not shown).
If ALDH enzyme activity (rather than expression of ALDH1A1) is the key factor 
for influencing the functional behaviour of breast cancer cells, then it is possible that a 
-12% subpopulation of ALDHhl cells is simply not a high enough proportion to influence 
the behaviour of whole population MCF-7/ALDH1A1 cells. To address this possibility, 
we assessed proliferation of the subpopulation with the highest ALDH activity in the 
MCF-7/ALDH1A1 cell line using an assay that allowed for single-cell readouts.
4.2.6 MCF-7/ALDH1A1 cells with the highest ALDH activity demonstrate a
significantly higher proportion of cells in the S/G2/M phases of the cell cycle
We developed a single-cell readout assay to indirectly assess whether or not the 
-12% ALDHhl subpopulation in the MCF-7/ALDH1A1 cell line could proliferate better 
than the remainder of the population. This flow cytometry assay combines the 
Aldefluor® Assay with cell cycle analysis via DRAQ5® (BioStatus Ltd). DRAQ5® is a 
live cell DNA stain that emits in the far red fluorescent region, and was chosen for use in
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Figure 16. MCF-7/ALDH1A1 cells contain only a small proportion of cells with 
high ALDH activity. The ALDH activity of various cell lines was assessed using 
the Aldefluor® Assay (n=3). A metastatic human breast cancer cell line, MD-MBA- 
468 was used as a positive control. A specific inhibitor of ALDH (DEAB) was used 
as a negative control. Only the MDA-MB-468 and the sorted MCF-7/ALDH1A1 
pooled populations demonstrated a significantly increased proportion of ALDHhl 
cells (68.3 ± 8.3% and 11.25 ± 1.99%, respectively) compared to MCF-7/pcDNA3.1 
cells. Data is presented as mean ± S.E. * = significantly different than MCF- 
7/pcDNA3.1 {p < 0.05).
cell cycle analysis because it does not require fixation and permeabilization of cells, and 
is thus compatible with the Aldefluor® Assay.
The gating strategy for flow cytometry analysis is shown in Figure 17A. MCF- 
7/ALDH1A1 cells were analyzed for ALDH activity and gated into three subpopulations. 
The first region (A) was set based on the DEAB negative control, and these cells were 
considered the '‘ALDH"” subpopulation. The second region (YZ) was gated as per our 
standard assays (Figure 9), again based on the DEAB negative control, and these cells 
were considered to be the "ALDHhl" subpopulation. Finally, the third region (Z) was 
gated on the top -20% of ALDHhl cells, and was thus considered “ALDHhlglKSt" 
subpopulation. Each of these gates was then subsequently analyzed for cell cycle status 
from the fluorescence of the DRAQ5® labelled nucleus. Cells that fall under the first 
peak, valley and second peak of the flow histogram were considered to be cycling in the 
Go/Gi, S, and G2/M phase, respectively (Figure 17, and Table 5).
The cell cycle status of each of the subpopulations is summarized in Table 3. We 
observed the highest proportion of ALDH" subpopulation of MCF-7/ALDH1A1 cells in 
the G0/G| phase, while we saw the lowest proportion of ALDHhlghest cells in this resting 
(G0/Gi) phase. Conversely, more of the ALDHhlghesl cells were cycling in the S, and G2/M 
phase, while the least proportion of ALDH" cells were cycling in these two cell cycle 
phases. Results from the S and G2/M phases were combined as well and we also found 
that more of the ALDHhlghcsl cells were cycling in the S/G2/M phase, while the least 
proportion of ALDH" cells were cycling in these combined non- Gq/G] phases.
Interestingly, we observed that the ALDHhlghcst subpopulation of cells (Figure 
17A, region Z) had statistically significantly more cells in the S, G2/M and S/G2/M phases 
and statistically significantly less cells in the Go/Gi phases of the cell cycle when 
compared to the remaining population of MCF-7/ALDH1A1 cells (ALDHhl and ALDH' 
subpopulations) as well as to the MCF-7/pcDNA3.1 empty vector control cells (Figure 
17B) (j7 < 0.05). No significant differences were observed between the ALDH' and 
ALDHhl MCF-7/ALDH1A1 populations, or between these populations and the MCF- 
7/pcDNA3.1 empty vector control cells cycling in any of the phases (Figure 17B\p> 
0.05). even though the ALDH' subpopulation had the lowest and highest proportion of 
cells in the S/G2/M and Go/Gi phase, respectively (Table 3). There were also no 




F ig u r e  17 . M C F -7 /A L D H 1 A 1  c e lls  w ith  th e  h ig h e s t  A L D H  a c t iv ity  
d e m o n s tr a te  a s ig n if ic a n t ly  h ig h e r  p r o p o r t io n  o f  c e lls  in  th e  S/Cty/M p h a se s  
o f  th e  ce ll cy c le . Using a flow cytometry based Aldefluor®/DRAQ5® assay, the 
empty vector control cells (MCF-7/pcDNA3.1) and the MCF-7/ALDH1A1 cells 
were analyzed for cell cycle and ALDH activity (n=3), as an indirect 
measurement of cellular proliferation. (A) Representative dot plots of MCF- 
7/ALDH1A1 cells labelled with the Aldefluor® substrate (right panels) or treated 
with the ALDH inhibitor DEAB (left panels). MCF-7/ALDH1A1 cells were 
analyzed for ALDH activity and gated into three subpopulations. The first region 
(A) was set based on the DEAB negative control, and these cells were considered 
the “ALDH"' subpopulation. The second region (YZ) was gated as per our 
standard assays (Figure 9), again based on the DEAB negative control, and these 
cells were considered to be the “ALDHhl" subpopulation. Finally, the third region 
(Z) was gated on the top -20% of ALDH1’1 cells, and was thus considered 
“ALDHhlghcst" subpopulation. (B) Cell cycle analysis of MCF-7/pcDNA3.1 and 
MCF-7/ALDH1A1 human breast cancer cells. Cells were serum starved for 48h, 
followed by addition of regular growth media with serum for 24h before being 
harvested for flow cytometry (Aldefluor®/DRAQ5®) analysis. Data is presented 
as mean ± S.E. a = significantly different than MCF-7/pcDNA3.1; [3 = 
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Table 3. P e r c e n ta g e  o f  c e lls  in  ce ll c y c le  p h a se  (M e a n  ±  S .E .M .)
Cell Cycle 
Phase
MCF-7/pcDNA3.1 ALDH ALDHhi ALDHhighest
Go/Gi 54.32 ± 0.47 57.70 ± 2.32 51.38 ± 2.23 38.29 ± 3.68
s 27.26 ± 0.62 24.41 ± 1.08 26.81 ±0.52 35.98 ± 1.62
G*/M 19.39 ± 0.87 17.88 ± 1.24 21.81 ± 1.72 25.73 ± 2.15
S/Gz/M 45.68 ± 0.48 42.30 ± 2.32 48.62 ± 2.23 61.7113.67
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5.0 DISCUSSION
Despite advances in prevention, early detection, and treatment of primary breast 
tumours, breast cancer remains the second leading cause of cancer death in Canadian 
women [1]. This is mainly due to the propensity of primary breast tumours to metastasize 
to distant sites of the body and the unfortunate fact that most current therapies fail in the 
metastatic setting. Metastasis is therefore a major contributing factor to breast cancer 
mortality [2-5].
The metastatic process involves a series of sequential steps, where all of these 
steps must be successfully completed by a cancer cell in order to give rise to a metastatic 
tumour in a distant organ. The steps of metastasis include intravasation into the blood or 
lymphatic system; survival in the circulation; arrest, adherence and invasion 
(extravasation) into secondary tissues; and finally initiation and formation of metastases 
[3, 5, 13]. Due to the complexity of metastasis and the multiple steps that a metastatic 
cancer cell must complete in order to be successful, it is not surprising that this highly 
lethal process is also an inefficient one. However, not all the steps are equally inefficient 
[2, 13-15]. Various studies in animals as well as humans have suggested that although the 
majority of cancer cells that escape the primary tumour may be able to survive in the 
circulation and extravasate into secondary sites, only a very small subset of these cells are 
able to initiate and maintain metastases in distant organs [14, 15, 20, 149]. Growing 
evidence suggests that the cells responsible for this process may be cells with cancer stem 
cell (CSC) properties, or “metastasis-initiating cells"'.
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Previous work in our lab indicates that stem-like breast cancer cells can be 
identified by an ALDHhlCD44+ phenotype, and that these cells are significantly more 
metastatic and more resistant to therapy than their ALDHlovvCD44" counterparts [6, 7], In 
the current study we began to interrogate the mechanisms underlying these observations 
by investigating the idea that ALDH is not simply a marker of highly aggressive breast 
cancer cells, but that it also plays a functional role that contributes to breast cancer 
metastasis. In particular, we tested the hypothesis that overexpression of the ALDH 
isoform ALDH1A1 in normally non-metastatic MCF-7 human breast cancer cells would 
result in an increase in metastatic behaviour in vitro. To the best of our knowledge, this is 
the first study to investigate the role of ALDH1A1 overexpression in mediating breast 
cancer cell malignancy.
5 . 1 S u m m a r y  o f  E x p e r im e n ta l F in d in g s
We first investigated the base activity/expression of both ALDH and the prospective 
breast CSC phenotype CD44+CD24" in MCF-7 human breast cancer cells. It was 
observed that MCF-7 cells had minimal ALDH activity (by flow cytometry) and low 
ALDH1A1 expression (by RT-PCR and western blot analysis). In addition, flow 
cytometry analysis demonstrated that MCF-7 cells did not express the breast CSC 
phenotype CD44+CD24". Taken together with non-metastatic nature of these cells [7, 
150], these results indicated that MCF-7 cells would provide a good candidate model 
system lor overexpression of ALDH1A1 in order to study its effects on breast cancer cell
metastatic behaviour.
Following cloning and construction of the ALDH1 Al/pcDNA3.1 mammalian 
expression vector, MCF-7 cells were subjected to liposome-based transfection in order to 
generate cells that stably expressed either ALDF11A1 (MCF-7/ALDH1A1) or an empty 
vector control (MCF-7/pcDNA3.1). Of the 57 ALDH1A1 colonies/clones that were 
selected for screening, only 4 clones demonstrated enhanced expression of ALDH1A1 by 
RT-PCR and immunoblotting relative to the empty vector control cells. These 4 positive 
clones were used to generate a pooled population in order to control for clonal 
heterogeneity. Correspondingly, 4 of the MCF-7/pcDNA3.1 clones (all negative for 
ALDH1A1 mRNA and protein expression) were also combined to generate a pooled 
population of empty vector control cells. Pooled MCF-7/ALDF11A1 cells were then 
sorted using FACS in an effort to enrich the population for high ALDH activity prior to 
use in functional assays.
Several assays were utilized to compare the in vitro metastatic behaviour of the 
pooled MCF-7/ALDH1A1 and MCF-7/pcDNA3.1 cell lines, including assays for cell 
proliferation (uncontrolled growth), migration, adhesion (components of extravasation), 
and colony formation (surrogate for colonization steps of metastasis). Despite the fact that 
MCF-7/ALDH1 Alcells demonstrated stable overexpression of ALDH1A1 at the 
transcript and protein level, the results of the functional assays for proliferation, 
migration, adhesion, and colony formation did not support our hypothesis that 
overexpression of ALDH1A1 would enhance the metastatic behaviour of breast cancer 
cells in vitro. When ALDH enzyme activity was investigated, it was revealed that only 
-12% of the MCF-7/ALDH1A1 pooled population were ALDHhl. Using serial FACS 
sorting to enrich the population for ALDH1'1 cells, we were unsuccessful at obtaining a
cell population with a stable ALDHhl population greater than -12%. To address the 
possibility that ALDH enzyme activity (rather than protein expression of ALDH1A1) is 
the key factor for influencing the functional behaviour of breast cancer cells, we assessed 
proliferation of the subpopulation with the highest ALDH activity in the MCF- 
7/ALDH1A1 cell line using an assay that allowed for single-cell readouts. Our results 
indicated that MCF-7/ALDH1A1 cells with the highest ALDH activity demonstrate a 
significantly lower proportion of ALDHhlghesl cells in the resting (Gq/G i) phase, and a 
significantly higher proportion of cells in the S, G2/M. and S/G2/M phases of the cell 
cycle compared not only to the empty vector control but also to other subpopulations 
within the MCF-7/ALDH1A1 cell line with lower ALDH activity. This suggests that cells 
with the highest ALDH activity are actively cycling and proliferating more than the 
remainder of the subpopulations and the empty vector control. Specifically, only the 
ALDHhlgllLSl cells were significantly actively synthesizing and replicating their genetic 
material more (in S-phase), while both the ALDH11' and ALDHlllghest cells were preparing 
to undergo mitosis (G2/M phase) at approximately the same rate. Therefore, this result 
also suggests that ALDHhl, and not ALDHlllghcst, are synthesizing their DNA at a faster 
rate as they are spending less time in S phase, and more time in the G2/M phase. 
Meanwhile, the ALDHlllglKSl cells are spending approximately the same amount of time in 




5 .2  Im p lic a t io n s  o f  th e  E x p e r im e n ta l F in d in g s
Overall, the majority of the findings of this thesis were not supportive of the 
central hypothesis that overexpression of ALDH1A1 would result in increased breast 
cancer cell metastatic behaviour, including increased proliferation, migration, adhesion 
and colony formation. This was unexpected, since the hypothesis was developed on the 
basis of previous published findings from our lab that demonstrated that breast cancer 
cells with an ALDHh'CD44+ phenotype show significantly enhanced metastatic behaviour 
in vitro (including increased proliferation, colony formation, adhesion, migration and 
invasion) and in vivo compared to their ALDHlmvCD44" counterparts [7], It is possible 
that perhaps CD44 and not ALDH is contributing to these aspects of metastatic behaviour 
[51, 55, 59, 151, 152], However, previous studies have shown that knockdown of 
ALDH1A1 in lung cancer cells results in decreased proliferation and migration [111], 
indicating that ALDH1A1 may have the capacity to influence at least some of the steps of 
the metastatic cascade, with or without CD44. Furthermore, subsequent studies by 
Charafe-Jauffret, et al. (2009, 2010) demonstrated that breast cancer cells with an 
ALDH1" phenotype alone (as opposed to ALDHh'CD44+) are also highly metastatic [72, 
139], thus supporting the rationale for our original hypothesis. Interestingly, preliminary 
results from our lab have shown that knock dowm of ALDH1 Al in MDA-MB-468 cells 
(which normally are moderately metastatic and have a relatively high ALDH activity and 
expression [7]). resulted in a decrease in proliferation, adhesion and migration; which are 
some of the steps of the metastatic cascade [153]. Thus taking together of previous 
findings from our lab as well as others, we were surprised at our unexpected results from 
this project.
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In trying to understand the outcome of this study, the following points must be 
considered in detail: (1) The ALDH activity of MCF-7/ALDH1A1 cells may not have 
been high enough to translate to a downstream functional effect; (2) ALDH1A1 may not 
the most important ALDH isoform contributing to the enzymatic activity measure by the 
Aldefluor® kit and/or contributing to metastatic behaviour; and/or (3) There is some sort 
of a negative feedback regulation of ALDH1A1 activity present in the MCF-7 cells. 
These possibilities are discussed in detail below. Furthermore, perhaps the CD44+ 
phenotype is required to assist ALDH in modulating metastatic behaviour, as currently 
we know that CD44 plays a functional role in metastasis [59, 61].
5.2.1 ALDH activity may not have been high enough to translate to a downstream 
functional effect
In this study, we observed a statistically significant upregulation of ALDH1A1 
expression at the RNA and protein level following stable transfection with the 
ALDH1 Al/pcDNA3.1 expression vector. However, when ALDH enzyme activity was 
investigated, it was revealed that only -12% of the MCF-7/ALDH1A1 pooled population 
were ALDHhl. Using serial FACS sorting (n=3) to enrich the population for ALDHhl 
cells, we were unsuccessful at obtaining a cell population with a stable ALDHhl 
population greater than -12%. Although this was statistically significantly higher than the 
empty vector control; when compared to the MDA-MB-468 positive control, in which 
-70% of the population was ALDH1’1, -12% seems relatively low. Although it is expected 
that the complete ALDH1A1 protein is being translated from the full length ALDH1A1 
cDNA insert in the ALDHlAl/pcDNA3.1 vector, perhaps not all of the translated
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ALDH1 Al protein is highly active at the enzymatic level, as enzymatic activity depends 
on various factors. Efficient reaction rates, correct reaction conditions, reaction specificity 
and regulation of enzymatic activity all play a role to determine the activity of an enzyme, 
where if one of those factors fail, the enzyme may not be as active, or active at all [154], 
One may also be concerned about the pcDNA3.1 mammalian expression vector itself and 
its effectiveness in overexpressing ALDH1A1 under the control of the CMV promoter. 
However, there have been many studies from other labs as well as our own that have 
shown that pcDNAS.l can be successfully used to overexpress proteins of interest [155- 
157],
If ALDH enzyme activity (rather than protein expression of ALDH1A1) is the key 
factor for influencing the functional behaviour of breast cancer cells, then it is likely that 
a relatively high proportion of the subpopulation must have high ALDH activity in order 
to see a functional effect. This notion parallels previous studies reported from our lab, 
where w'e observed that both the MDA-MB-468 and MDA-MB-231 human breast cancer 
cell lines have a high proportion of the subpopulation that is ALDH1'1 (-70% and -80% 
respectively), and both of these cell lines have a medium to high metastatic capacity in 
vitro (proliferation, migration, adhesion, invasion, colony formation) as well as in vivo 
[7], Interestingly, other studies that modified the expression of ALDH in cancer cell lines 
to study its effects on drug resistance found that although the protein expression levels 
correlated to enzymatic activity when using the traditional method of measuring ALDH 
activity by lysing the cells and measuring the conversion of propionaldéhyde substrate 
into carboxylic acids using spectrophotometry [62. 76, 79, 80, 111, 112], ALDH activity 
was not consistently high [80, 112], This is despite seeing a significant effect the
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modified ALDH expression had on drug resistance in these cancer cell lines. Thus 
perhaps in the normally non-metastatic MCF-7 cell line, a higher ALDH activity may be 
needed in order to see downstream functional and malignant effects.
5.2.2 ALDH1A1 may not the most important ALDH isoform
Another possibility that might help to explain the largely negative findings of this 
study is the idea that ALDH1A1 may not the most important ALDH isoform contributing 
to the enzymatic activity measured by the Aldefluor® kit and/or contributing to the 
metastatic behaviour of breast cancer cells. We initially decided to focus our attention on 
the ALDH1A1 isoform for several reasons. Previous studies have demonstrated that high 
cytosolic ALDH1A1 and ALDH3A1 expression and/or activity can offer cellular 
protection against cytotoxic drugs in preclinical model systems [44, 65, 79, 144], as well 
as affecting the malignant behaviour of cancer cells [111]. Additionally, in two 
independent studies analyzing 163 and 269 primary prostate cancer patient samples 
(respectively), it was shown that patients with high ALDH1A1 expression had a higher 
Gleason score, higher pathologic stage, and reduced overall survival [104, 105. 144], 
indicating an association with more aggressive disease. Finally, the Aldefluor® assay was 
developed to detect ALDH activity generated predominately by the ALDH1A1 isoform 
(personal communication, StemCell Technologies).
However, during the course of the current thesis, a study w as published by Marcato et 
al. (2011) that suggested that other ALDH isoforms, in particular ALDH 1 A3, are also 
important. This study investigated the expression of all 19 ALDH isoforms in breast
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cancer patient samples and breast cancer cell lines using microarray analysis validated by 
qPCR and immunofluorescence protein expression studies. The authors demonstrated that 
the ALDH activity of patient breast tumour CSCs and cell lines correlated best with 
expression of ALDH 1 A3 rather than ALDH1 Al. They then carried out shRNA 
knockdown of the various isoforms and found that only ALDH 1 A3 knockdown 
consistently reduced ALDH activity of breast cancer cells as measured by the Aldefluor® 
assay. Immunohistochemical analysis of patient breast tumour tissues demonstrated that 
ALDH1A3 expression in patient breast tumours correlated significantly with tumour 
grade, metastasis, and cancer stage; while ALDH 1 Al was a comparatively poorer 
prognostic marker [158], However, this group did not investigate the direct functional 
impact of different ALDH isoforms in influencing the metastatic behaviour of breast 
cancer cells.
Interestingly, recent preliminary data from our lab indicates that when ALDH 1 Al 
is knocked down via siRNA in metastatic MDA-MB-468 human breast cancer cells, there 
is a significant decrease in proliferation, migration, and adhesion when compared to cell 
lines transfected with a scrambled siRNA control, although there is no corresponding 
decrease in ALDH activity as measured by the Aldefluor® assay [153], While the ALDH 
activity results are consistent with the Marcato et al. (2011) study discussed above [158], 
the results of the functional studies are discordant with the results of the current thesis 
work. It is possible that there are cell line specific differences that influence the role of 
different ALDH isoforms in mediating breast cancer cell behaviour, and/or negative 
feedback mechanisms at play in the presence of overexpressed ALDH 1 A l.
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5.2.3 There may be negative feedback regulation of ALDH1A1 activity
As mentioned earlier, even when the MCF-7/ALDH1A1 cell line w'as enriched via 
FACS in three consecutive cell sorting experiments, the highest stable proportion of 
ALDHhl cells that was achieved was ~12%. Based on this, we hypothesized that a 
negative feedback regulation of some sort was behind this effect. Retinoid signalling 
pathways have been implicated in cancer [78, 79, 117, 118], and ALDH1A1 transcription 
is under the negative feedback regulation of the retinoic acid (RA) signalling pathway 
[68, 121], ALDH is involved in the conversion reaction of retinaldehyde (retinal) to RA 
[119], Retinol is first oxidized by alcohol dehydrogenase (ADH) to retinal, and this 
process is reversible. Retinaldehyde is then irreversibly oxidized to RA by cytosolic 
ALDI11A1. The latter reaction is a tightly regulated process that is tissue-specific, since 
the oxidation of retinaldehyde to RA is an irreversible reaction, with RA having a potent 
biological activity [91, 119], The resulting RA produced can then act on nuclear retinoic 
acid receptor (RAR)-a, [3, y, and retinoid X receptor (RXR)-a, [3, y, which bind DNA as 
heterodimers and result in the regulation of gene expression and cell differentiation [119, 
121]. When there are low intracellular RA concentrations. RARa and CCAAT/enhancer- 
binding protein (C/FiBP[3) transactivate the Raldhl promoter (murine Raldhl has similar 
tissue-specificity and developmental control as the cytosolic human ATDH1 [121]), 
thereby increasing the ALDH activity to increase the oxidization of retinaldehyde to 
retinoic acid. As RA levels increase, C/EBPP mRNA increases, which also increases 
GADDI 53 mRNA. A complex of GADDI 53 and C/EBPp then forms to decrease DNA 
binding activity of C/EBP[3 to the CCAAT box of the ALDH1 promoter, thereby 
inhibiting the transactivation of ALDH 1. This ultimately results in a decrease in RA
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synthesis [68, 121], Furthermore, previous results from our lab also showed that 
exogenous aU-trans retinoic acid (ATRA) was able to inhibit intrinsic ALDH activity of 
metastatic human breast cancer cell lines, thus resulting in an increased sensitivity of 
those cell lines to chemotherapy and/or radiation therapy [6].
However, if the RA negative feedback mechanism does play a role in regulating the 
proportion of the ALDH1" subpopulation MCF-7/ALDH1A1 cells, one might ask the next 
logical question: is there any retinol and/or retinal (retinaldehyde) available to the MCF- 
7/ALDH1A1 cells while in culture to inhibit ALDF1 activity? Investigation of the 
composition of the DMEM + 10% FBS media that was used to maintain MCF-7 cells 
revealed that there was no exogenous retinol or retinal present. Although this does not 
indicate there is absolutely no retinol/retinal present during culture of these cells, perhaps 
there are other possible mechanisms of negative feedback inhibition of ALDH activity, 
such as the estrogen receptor (F/R) signalling pathway. Recent evidence suggests there is 
a correlation with HR" breast cancer cells and the presence of an ALDH1" population 
[110], as well as a correlation between aggressive breast cancer cell lines and negative ER 
status [7, 159], Morimoto, el al. in 2009 investigated the clinicopathological 
characteristics of primary breast cancers with ALDH1" cancer stem-like cells [110], Using 
immunohistochemical staining, ~10% of the 203 breast cancer patient samples were 
found to be ALDH1", and these cells were significantly more likely to be ER'. Patients 
with ALDH1" tumours had a worse prognosis than patients with ALDH10" tumours [110], 
Our lab has found that both the MDA-MB-231 and -468 cell lines contain a high 
proportion of ALDH1" cells, and are both metastatic [7], Interestingly both of these cell 
lines are ER‘, whereas parental MCF-7 cells are ER+ [159]. Although this ER'/ALDH1"
correlation does not apply to every breast cancer cell line (for example, SKBR3 is ER- 
but is non-metastatic [159]), we decided to investigate whether the ER signalling pathway 
may be playing a role in the negative feedback regulation of ALDH activity in the sorted 
MCF-7/ALDH1A1 cell lines. We are currently investigating this further, and the 
promising preliminary results are described in detail in the Future Directions section 
below.
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6.0 POSSIBLE LIMITATIONS TO THE STUDY
The proposed conclusions and possible reasons for the observations seen in the in 
vitro assays of metastasis rely on certain assumptions made based on the design of the 
current experimental system. However, there are limitations as to how far we can draw 
these conclusions from the current system. The first limitation is related to the approach 
taken for overexpression of ALDH1A1. The results of this project relied on stable 
overexpression of ALDH1A1 in the MCF-7 cell line, which normally has low 
endogenous expression and activity of ALDH. Results of this study could have been 
strengthened by stably overexpressing ALDH1 A l, or as we now believe, other isoforms, 
in various breast cancer cell lines that normally have low endogenous levels and activity 
of ALDH to see if we obtain similar results, for example in SKBR3 cells [109], Prior to 
stably transfecting ALDH1 Al into MCF-7 cells, we could have tried transient 
transfections first to see if this was an effective method to stably overexpress ALDIH Al. 
However, when we tried using both the Lipofectamine 2000® as well as microporation 
method to transiently overexpress ALDH1 A l, we saw similar levels of ALDH activity 
that were observed in the stably transfected cells (data not shown). Another reason why
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we did not pursue the transient method to determine the functional role of overexpressed 
ALDH1A1 was because of potential downstream applications of the stably transfected 
cells in in vivo studies. Perhaps we should have tried a more powerful transfection 
method such as viral transduction. However, we did not pursue this route as we felt that 
viral transduction may lead to non-physiological levels overexpression of ALDH1A1, as 
well as having potential issues downstream if we wanted to pursue in vivo experiments 
with these MCF-7 cells that stably overexpressed ALDH1A1. This current experimental 
model system was also based on pooled populations of the clones with overexpressed 
ALDH1A1 at the mRNA, protein and activity level. One would argue that perhaps we 
should have studied ALDH1A1 in clonal populations, rather than pooled populations to 
strengthen our study. However, we decided to pool our clones positive for ALDH1A1 to 
control for clonal heterogeneity, as well as try and mimic the heterogeneous nature of 
cancer [8, 10],
The second limitation relates to the type of assays used for assessing changes in 
breast cancer cell malignancy. Although we were able to develop a quantitative assay that 
allowed for single cell readouts to determine the proliferative properties of MCF- 
7/ALDH1A1 cells with the highest ALDH activity, this was not possible for the migration 
(scratch wound), adhesion, and colony formation assays due the unavailability of good 
specific antibodies against ALDH1A1 for immunofluorescence. Therefore, although the 
single-cell cell cycle analysis using DRAQ5®/Aldefluor® may support our hypothesis 
that increased ALDH may result in increased proliferation, we cannot fully answer our 
scientific inquiry due to the lack of single cell results for the remaining assays in question.
Third, we tested our hypothesis using a solely gain-of-function (overexpression) 
approach in non-metastatic breast cancer cells that normally have low basal levels of this 
enzyme rather than also including a loss-of-function (knockdown) approach in highly 
metastatic cells with high basal levels of ALDH. This flaw in experimental design was 
the consequence of project design in the Allan lab, where the overexpression studies were 
done in this thesis project, and the knockdown studies (as described above) were carried 
out independently by another graduate student in the lab.
Finally, because this study was based on in vitro studies, an obvious limitation to 
this experimental design was that it lacked in vivo studies. However, because of the 
observations seen in this project, perhaps in vivo studies were not possible at this point, 
but should still be considered in the future with either overexpression or knockdown of 
ALDH1A1 and other ALDH isoforms in human breast cancer cell lines to determine if 
changes in these enzymes will result in a change in metastatic burden in 
immunocompromised animals compared to control.
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7.0 FUTURE DIRECTIONS
Based on the results and discussion thus far, it is clear that there are many possible 
experiments that we could do to further our know ledge and understanding of how ALDH 
plays a functional role in breast cancer metastasis so that we can develop therapies in the 
future to treat and/or prevent metastasis in patients.
First and foremost, assays that allow for single cell readouts must be developed 
for the migration, adhesion and colony formation assays in order to see if our hypothesis
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can be supported. Although we have tried 3 different commercially available anti- 
ALDH1A1 antibodies in an attempt to perform immunofluorescence-based single cell 
assays, the antibodies so far have given non-specific results. Thus other antibodies against 
ALDH1A1 will be tested in the lab until a specific antibody can be found and single cell 
assays can be developed for migration, adhesion and colony formation.
Our hypothesis was that overexpression of ALDH1A1 would increase the 
malignant behaviour of breast cancer cells that normally are not metastatic or aggressive. 
Conversely, our lab is also currently investigating the effects that knockdown of 
ALDH1A1 has on breast cancer metastasis as we hypothesize that knockdown of 
ALDH1A1 would result in a decrease in malignant behaviour of normally aggressive and 
metastatic breast cancer cells. Recent evidence from other groups [158] as well as this 
project have raise the question of whether or not other ALDH isoforms may also be 
important in breast cancer. Thus we are also currently carrying out knockdown 
experiments targeting ALDH1 A3 and ALDH3A1 to detennine if these isofonns play a 
functional role in determining ALDH activity and malignant breast cancer cell behaviour 
in vitro and in vivo.
As described earlier in the thesis, a possible reason why no significant functional 
differences in malignant breast cancer cell behaviour were observed between the MCF- 
7/ALDH1A1 cell line and the empty vector control may be due to a potential feedback 
regulation of ALDH activity in these cells. Recently there has been evidence showing a 
relationship between cells that are ALDHhl and ER" [110]. Since MCF-7 cells are ER+, 
perhaps overexpressing ALDH1A1 in an ER+ cell line may not be an effective method, as 
the ER signalling pathways may play a role in inhibiting ALDH activity. Thus I
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hypothesized that inhibiting ER using the pan-estrogen receptor antagonist ICI 182780 
[160] may increase ALDH activity. To test this hypothesis, MCF-7/ALDH1A1 cells were 
cultured in normal selective media or phenol-red free selective media (as phenol red has 
been shown to be an estrogen mimetic [161]) and treated with ICI 182780 (ICE Trocris 
Bioscience; a kind gift from Dr. Bonnie Deroo) for 48h before ALDH activity was 
assessed using the Aldefluor® Assay. As controls, cells were treated with DEAB; DMSO 
+ DEAB; ICI + DEAB; or Aldefluor only (n=3). Although there appeared to be a trend 
towards higher ALDH activity when ER was antagonized, there w'as no significant 
difference between the cells treated with ICI or its controls (p > 0.05; Appendix Figure 1, 
left). The same experiments were repeated for the MCF-7/pcDNA3.1 empty vector 
control cells, and again no significant differences were observed in ALDH activity upon 
treatment with ICI or its controls (data not shown). Although no significant differences 
were observed in this set of experiments, perhaps estrogen receptor (ER) expression may 
play a specific role in regulating ALDH at the transcript and protein level. Thus 
immunoblotting was also performed on MCF-7/ALDH1A1 (Appendix Figure 1, right) 
and MCF-7/pcDNA3.1 cells (data not shown) treated with/without ICI or with/without 
DMSO. with some promising results suggesting that ER may play a role in inhibiting 
ALDH at the protein level. RT-PCR should also be performed in the future on cells 




The current study investigated the hypothesis that overexpression of ALDH1A1 
would enhance the metastatic behaviour of breast cancer cells in vitro. To the best of our 
knowledge, this is a novel study as we are the first to investigate the functional role of 
ALDH in breast cancer metastasis by overexpression of ALDH1A1. Although the 
majority of the results did not support our hypothesis, the study revealed some very 
important questions that need to be investigated and have laid a solid groundwork for 
ongoing studies in our laboratory that are aimed at fully understanding the role that 
ALDH plays in breast cancer metastasis. The current study has contributed to the field 
where most of the literature is focused on the drug resistance roles that ALDH play in 
cancer. It would appear that ALDH may also play a direct functional role in breast cancer 
metastasis, such that a high ALDH activity in cells may result in increased proliferation. 
Future studies stemming from this project, as well as ongoing research in our lab, will 
hopefully soon add to the field that a high ALDH activity is directly related to metastatic 
behaviour, in addition to playing a role in drug resistance. Once we fully understand the 
process of breast cancer metastasis, we hope that ultimately we are able to develop novel 
therapeutic targets that can help treat or prevent metastasis in cancer patients.
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Appendix Figure 1. Treatment with the pan-ER antagonist ICI 182780 does not 
significantly alter ALDH activity but may enhance ALDH1A1 expression. MCF- 
7/ALDH1A1 cells were cultured in normal selective media (A, top) or phenol-red 
free selective media (A, bottom) and treated with a pan-estrogen receptor antagonist, 
ICI 182780 (ICI) for 48 h before ALDH activity was assessed using the Aldefluor® 
Assay. As controls, cells were treated with DEAB; DMSO + DEAB; ICI + DEAB; or 
Aldefluor® only (“ALDH”) (n=3). Although there appeared to be a trend towards a 
higher ALDH activity when inhibiting ER, no significant difference between 
treatment groups was observed (p > 0.05). Immunoblotting was performed on MCF- 
7/ALDH1A1 cells cultured in normal selective media (B, top) or phenol-red free 
selective media (B , bottom) treated with/without DMSO or ICI to detect ALDH1A1 
and actin (loading control) at the protein level. It would appear treatment of MCF- 
7/ALDH1A1 cells with ICI resulted in an increase in ALDH1A1 protein expression 
levels when compared to the cells only and DMSO controls (n=3).
